WO2020239083A1 - Aerosol generation or smoking system, or electronic cigarette and device thereof - Google Patents

Abstract

Disclosed are an aerosol generation material and a device for making the aerosol generation material smoke, or vaporizing, atomizing or aerosolizing the aerosol generation material. The aerosol generation material comprises composition Ⅰ, which contains a pharmaceutically acceptable nicotine salt and a pharmaceutically acceptable aerosol or smoke generation agent, and composition Ⅱ, which contains a pharmaceutically acceptable alkali, the alkalinity of which is stronger than the nicotine (the pKa value thereof being greater than the pKa value of the nicotine), and a pharmaceutically acceptable aerosol or smoke generation agent, wherein compositions I and II mentioned above are both inhaled by users/consumers in a smoked, vaporized, atomized or aerosolized state. The aerosol has full strength, good physiological satisfaction, low or no choking sensation, and low or no irritation, passes through the throat well, and has high nicotine bioavailability, and good consumer experience.

Description

Aerosol generation or aerosolization system or electronic cigarette and its device Technical field

The present invention relates to an aerosol generation or aerosolization system or an electronic cigarette and a device thereof, and more specifically, to an aerosol generation or aerosolization system or an electronic cigarette and a device thereof that are well experienced by consumers.

Background technique

In recent years, with the awareness of the harmful effects of smoking, government agencies, various health groups and other interested organizations have carried out many campaigns and plans to promote information about the harmful effects of smoking. Moreover, as a result of the recognition of the harmful effects, there have been many projects involving attempts to reduce the incidence of smoking.

The most beneficial thing a serious smoker can do is to reduce or preferably even stop smoking altogether. However, experiments have shown that most smokers find it extremely difficult, because most smoking leads to dependent diseases or addiction. WHO has a diagnosis called tobacco dependence in its International Classification of Diseases. Others, such as the American Psychiatric Association, call it addictive nicotine dependence. It is generally accepted that these difficulties in stopping smoking are caused by heavy smokers' dependence on nicotine.

Nicotine is an important material basis for the sensory quality of tobacco and tobacco products. Nicotine can act on the human central nervous system to cause corresponding physiological reactions. A proper amount of nicotine intake can refresh the brain, eliminate pain and increase nerve excitement. Long-term use can cause addiction.

The application of nicotine can bring satisfaction, and the conventional method is by smoking, such as smoking cigarettes, cigars or pipe tobacco, or by smelling or chewing tobacco. However, due to the formation of a large amount of harmful substances during the burning of tobacco, such as carcinogenic tar products, carbon monoxide, aldehydes and hydrocyanic acid, smoking has serious health risks. Therefore, it is desired to form an alternative way of comfortable administration of nicotine, which can be used to promote Quit smoking and/or replace smoking.

With the continuous development of the global tobacco control movement, a variety of relatively healthy cigarettes/nicotine substitutes continue to emerge, of which electronic cigarettes are the most popular. The core part of e-cigarettes is electronic cigarette liquid. The smoke produced by the e-liquid under the action of an atomizer is similar to real smoke smoke, but it is well known that it does not contain harmful substances such as tar and carbon monoxide.

At present, the main components of e-cigarette liquid are usually solvents (propylene glycol and glycerol, the total content is generally more than 90%), nicotine (generally content is 0-3%) and flavor substances (according to different tastes, such as tobacco, Mint, coffee, fruit, etc., add different fragrance ingredients). At present, most of the e-cigarette liquids sold on the market are too sweet and greasy in the mouth after inhalation, the tobacco flavor is too weak, and the strength is insufficient, which cannot meet the needs of consumers, which severely restricts the development of e-cigarettes. The main reason is that the content of free nicotine in the smoke liquid is too small.

Nicotine in electronic cigarettes exists in two forms, free state and bound state. Cigarette strength is related to the content of nicotine in tobacco and mainstream smoke, especially the free nicotine in it. The physiological satisfaction of cigarette smoking is mainly determined by the total intake of nicotine and the speed at which it enters the blood system. In 1970, Armitage et al. found that free nicotine is more lipophilic than proton nicotine, and it is easier to penetrate the oral mucosa and be absorbed by the body more quickly. The intensity of physical stimulation and the intensity of smoke produced during smoking are related to the content of free nicotine in the smoke. The higher the content, the greater the intensity.

Patent CN201510942417.4 discloses an e-cigarette liquid containing a pH adjuster, the e-cigarette liquid includes 1-10% by mass of a pH adjuster, and the pH of the e-cigarette liquid is pH 7.2 to pH 8. 9. The e-cigarette liquid increases the release of free nicotine and improves the physiological satisfaction of the e-cigarette to a certain extent. However, nicotine is easy to oxidize and degrade, easy to volatilize, and has poor throat and oral properties.

Patent CN104473322A "discloses an e-cigarette liquid containing nicotine and organic acid: nicotine, organic acid and e-cigarette-forming agent are mixed uniformly in proportions to obtain e-cigarette liquid; among them, 1ml of e-cigarette liquid The content of base is 1-30mg; the organic acid is monocarboxylic acid or dicarboxylic acid; the molar ratio of monocarboxylic acid to nicotine is not more than 0.5, and the molar ratio of dicarboxylic acid to nicotine is not more than 0.25". This technology attempts to "mix nicotine, organic acids and aerosols to form organic acid nicotine salts, and then through the heating process of e-cigarette smoking, evaporate volatile organic acids or decompose them into free nicotine to compensate for the smoke. Uniformity of alkali release". However, the above process is difficult to occur in actual use, because the degradation temperature of nicotine salt is much higher than the boiling point of the atomizing agent (such as propylene glycol, glycerin or water or ethanol), nicotine salt can only be atomized. The agent is atomized together, even if heated to the degradation temperature of the nicotine salt, it is difficult to pyrolyze into nicotine, and it is more likely to produce many other pyrolysis products, because the pyrolysis process is carried out randomly in the molecule.

It needs to be pointed out that the free nicotine is easily oxidized and degraded, and is easily volatile. It has a strong choking sensation and a spicy taste. As the content of free nicotine increases, e-cigarette liquid has poorer throat-passing properties, and consumers may refuse to use it, resulting in "resistance". Although the nicotine salt has good stability and no throat choking, it has a bitter taste, poor taste and irritation. It is difficult to inhale into the brain through the mucous membrane due to poor lipophilicity, and it is difficult to produce physiological satisfaction.

Therefore, in reality, there is a need for an electronic cigarette that has good physical satisfaction, low or no choking sensation, low or no irritation, good throat penetration, and good consumer experience.

Summary of the invention

The purpose of the present invention is to provide an electronic cigarette that is full of energy, good physiological satisfaction, low or no choking sensation, low or no irritation, good throat passage, and good consumer experience.

Based on the above objective, the inventors unexpectedly discovered through research that a solution of nicotine salt (bound nicotine) and a solution of a more alkaline alkali than nicotine both meet in the body, especially in the alveoli, in an atomized state. , Can produce free nicotine on site, can significantly reduce or eliminate choking sensation, can significantly reduce or eliminate irritation, significantly improve throat, "strength" and physiological satisfaction, and significantly improve consumer experience; at the same time, The content of free nicotine with high volatility in the nicotine solution is greatly reduced or almost zero, which can significantly improve the stability of nicotine and reduce the volatilization of free nicotine from the nicotine solution, which is beneficial to stabilize the nicotine in the nicotine solution Total content. Based on the above findings, the present invention has been completed.

The present invention relates to a kind of (strength and feet, good physiological satisfaction, low or no choking sensation, low or no irritation, good throat passage, high nicotine bioavailability (bioavailability), and good consumer experience ) Electronic cigarette (or aerosol generating system/material), characterized in that the electronic cigarette (or aerosol generating system/material) comprises a pharmaceutically acceptable nicotine salt and a pharmaceutically acceptable aerosol or Smoke generating agent composition (I) and containing a pharmaceutically acceptable base stronger than the nicotine (its pKa value is greater than the pKa value of the nicotine) and a pharmaceutically acceptable aerosol or smoke generating agent The composition (II), (the above compositions (I) and (II) are separated from each other and not blended together), the above compositions (I) and (II) (both are aerosolized or vaporized or aerosolized or After being aerosolized), they are inhaled (in the body (especially in the lungs (alveoli))) in aerosolized or vaporized or aerosol or aerosol (aerosol) state (in the body (especially in the lungs (alveoli))), (in the use (/ (Consumers) meet in the body (especially in the lungs (alveoli)) (to produce free nicotine)). The above electronic cigarette (or aerosol generating system/material) also includes a device (kits, device, equipment, unit, etc.) that can aerosolize or vaporize or aerosolize or aerosolize the above compositions (I) and (II). ).

The above composition (I) or (II) is a solid, semi-solid or liquid mixture or solution (at room temperature 25℃), and when the above composition (I) or (II) is solid (at room temperature 25℃), its dosage form It can be powder, granule, tablet (including block, special-shaped tablet), and capsule.

The above-mentioned compositions (I) and (II) are respectively aerosolized or vaporized or aerosolized or aerosolized by two independent and unconnected atomization subsystems.

Detailed ways

Compositions containing pharmaceutically acceptable nicotine salts of tobacco leaf materials (such as cut tobacco, tobacco dust, etc.) can also be used in the present invention.

Nicotine in the present invention means 3-(1-methyl-2-pyrrolidinyl)-pyridine, including synthetic nicotine and nicotine extracts from tobacco plants or parts thereof, such as Nicotiana alone or a combination thereof.

The nicotine salt used in the present invention generally refers to a pharmaceutically acceptable salt of nicotine, including its pharmaceutically acceptable inorganic acid salt and organic acid salt. The pKa value of the above acid is lower than the pKa value of nicotine, preferably Low 0.5 or more, more preferably 1 or more, and most preferably 2 or more.

Examples of the above-mentioned pharmaceutically acceptable organic acids are as follows:

1) Alkanes or cycloalkane polycarboxylic acids with C2-C7 atoms (preferably C2-C6):

Such as cis or transmethyl butenedioic acid, dihydroxy cis or fumaric acid, maleic acid (maleic acid), fumaric acid (fumaric acid, fumaric acid, fumaric acid) ), galactonic acid, glucaric acid, itaconic acid (alconic acid), malic acid, adiponic acid (muconic acid), oxalic acid, malonic acid, succinic acid (succinic acid), Glutaric acid, adipic acid, oxalic acid (pyruvate), oxalic acid (oxaloacetic acid, ketone dioic acid), ketoglutarate, hexanodioic acid, diethyl malonic acid, citric acid, tartaric acid , Aconitic acid, citramalic acid (2-Hydroxy-2-methylbutanedioic acid), dihydroxytartaric acid,

2) Alkanes or cycloalkane monocarboxylic acids with the number of atoms of C2-C14 (preferably C2-C6):

Such as acetic acid, propionic acid, isopropionic acid, butyric acid, isobutyric acid, n-valeric acid, isovaleric acid, valproic acid, caproic acid, isohexanoic acid, n-heptanoic acid, isoheptanoic acid, lactic acid, acrylic acid, butene Acid, methacrylic acid, pivalic acid (trimethylacetic acid), 2,2-dimethylolpropionic acid, gluconic acid, D or L-gulonic acid, glycolic acid, D-lactic acid, L-lactic acid, hydroxy Butyric acid (such as α-, β-, γ-type), hydroxyvaleric acid (such as α-, β-, γ-type), hydroxycaproic acid (such as α-, β-, γ-type), dihydroxyvalerate Acid, dihydroxycaproic acid, trihydroxycaproic acid, caprylic acid, capric acid, lauric acid, palmitic acid,

3) The hydrogen on the ring of the molecular structure of the benzene compound is covered by one or more carboxyl groups with carbon atoms of C1～C7 (more preferably C1～C6) linear or branched (preferably linear predominant) alkane or cycloalkane group, one Or polycarboxyl group or polyhydroxy group with carbon atoms of C2-C7 (preferably C2-C6) linear or branched alkane (preferably straight-chain predominant) hydrocarbon or cycloalkane substituted with the highest carbon atom in the alkane chain in the molecular structure The number of carboxylic acids not higher than C7 (preferably C6):

Such as anisic acid (methoxybenzoic acid), o-phenyllactic acid, benzhydryl acid, benzoic acid, caffeic acid, o/or p/or m-methyl salicylic acid, salicylic acid, acetylsalicylic acid, Ferulic acid, high oxalic acid (4-Hydroxy-3-methoxybenzeneacetic acid), 4-hydroxyisophthalic acid, phenylpropionic acid, p-hydroxybenzoic acid, isophthalic acid, mandelic acid (mandelic acid), benzene Hexacarboxylic acid, 4,6-dihydroxy-2-methylbenzoic acid (bryoic acid), phenylacetic acid, protocatechuic acid (3,4-dihydroxybenzoic acid), cumene acid (insoluble), gallic acid, 2,5-dihydroxybenzoic acid, 2,5-dihydroxyphenylacetic acid,

4). The hydrogen on the molecular structure of furan compounds, pyran compounds and pyrone compounds is linear or branched (preferably straight chain) by one or more carboxyl groups with carbon atoms of C1～C7 (more preferably C1～C6) ) Alkane or cycloalkane group, one or more carboxyl group, one or more hydroxyl carbon atoms are C2～C7 (more preferably C1～C6) linear or branched (preferably straight chain is predominant) alkane or cycloalkane substituted And the highest carbon number of the alkane chain in the molecular structure is not higher than C7 (preferably C6) carboxylic acid:

Such as dihydrochalcone, 2-furan acrylic acid, furan carboxylic acid, D-galacturonic acid, glucuronic acid, a-pyrone-5-carboxylic acid,

5) Ascorbic acid, dehydroascorbic acid, (6-)deoxy-L-ascorbic acid, glucose-type ascorbic acid, erythorbic acid,

6) In other molecular structures, organic acids with the highest carbon number of the alkane chain not higher than C7 (preferably C6, more preferably straight chain dominant):

Such as angelic acid ((Z)-2-methyl-2-butenoic acid), camphor acid (diacid), butylmalonic acid, carboxyglutamic acid (carboxyglutamic acid, polycarboxylic acid), cinnamic acid , Coumaric acid (o/or p/or m-hydroxy benzene acrylic acid), coumaric acid (oxyindene acid, benzofuran carboxylic acid), monoethyl tartaric acid, glucoheptonic acid, glycolic acid, glycyrrhizic acid, Glyoxylic acid hydrate, hydroxyglutamic acid, 1-hydroxy-2-naphthoic acid, 3-hydroxy-2-naphthoic acid, iminodisuccinic acid, indoleacetic acid, isonicotinic acid, 2-keto-L-gu Lonic acid, kojic acid, lactobionic acid, trimethylacetic acid (trimethylacetic acid, pivalic acid, glutaric acid, pivalic acid), prephenic acid (1-carboxy-4-carboxy-2,5-ring Hexadiene-1-pyruvate), reducing acid (1,2-dihydroxy-3-ketocyclopentene), quinic acid, trans-2-butenoic acid (crotonic acid), sorbic acid, edetic acid , Triamine pentaacetic acid, pimelic acid, clavulanic acid, ribonucleotides, deoxynucleotides, inosinic acid, α-methyl furanosinic acid, adenine nucleotides (adenylic acid, AMP), bird Purine nucleotides (guanylic acid, GMP), cytosine nucleotides (cytidine acid, CMP), uracil nucleotides (uridine acid, UMP), thymine nucleotides (thymidylic acid, TMP) , Inosine nucleotides (inosinic acid, IMP), xanthine nucleotides, tyrosine, tryptophan, cystine, phosphorylated amino acids (such as phosphotyrosine, phosphoserine and phosphothreonine) ) And acidic amino acids (such as glutamic acid, aspartic acid),

7) And the acid salt or acid salt of the above-mentioned polybasic organic acid.

Examples of organic acids that are preferably used in the present invention to form nicotine salts with nicotine are malic acid, glycyrrhizic acid, tartaric acid, gluconic acid, oxalic acid, galactonic acid, glucaric acid, glutamic acid, aspartic acid, benzene Formic acid, ascorbic acid, dehydroascorbic acid, (6-)deoxy-L-ascorbic acid, glucose-type ascorbic acid, erythorbic acid. Because they have a better taste, or/and lower irritation or/and higher stability.

Preferred examples of the following pharmaceutically acceptable inorganic acids are as follows:

Hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, pyrosulfuric acid, sulfurous acid, pyrosulfurous acid, thiosulfuric acid, bisulfate, dihydrogen phosphate, bisulfite, benzenesulfonic acid, sulfosalicylic acid.

Volatile organic acids are particularly preferred for use in the present invention. Examples of available volatile organic acids are formic acid, acetic acid, benzoic acid, phenylacetic acid, caprylic acid, propionic acid, butyric acid, isobutyric acid, methylbutyric acid, valeric acid, isovaleric acid, methylvaleric acid, caproic acid, Of the isohexanoic acid, benzoic acid, 2-methylbutyric acid, valeric acid, isovaleric acid, 3-methylvaleric acid, phenylacetic acid, isovaleric acid, and caprylic acid are most preferred. This is because the increase in isovaleric acid content is conducive to pleasure and not conducive to the improvement of sweetness; increasing the content of 2-methylbutyric acid and valeric acid is conducive to the reduction of odor and irritation; phenylacetic acid is conducive to the concentration of Increase; and bitterness has a positive effect on concentration and strength.

Many preparation methods of nicotine salts are known and can be used, such as CN1607950A, CN101222915A, CN201480025499.X, CN201580038462.5, CN201180028544.3, CN201680079884.1, CN201180022735.9, CN03812809.8, etc. Alkali salt.

The preparation method of nicotine salt can also adopt the following simple methods:

Take excess or slightly excess nicotine (free state) and mix it with an acid (pKa value lower than nicotine) aqueous solution. After the reaction is basically completed (the pH value of the solution is determined to show a stable alkaline value) the solution is spray-dried (normal temperature to 150℃) ) Or freeze spray drying to remove the moisture and excessive volatile nicotine to obtain nicotine salt.

Table 1 Examples of acids that can be used in the present invention to form salts with nicotine

Acid that can form salt with nicotine Molar ratio of acid:nicotine* Acid that can form salt with nicotine Molar ratio of acid:nicotine* Formic acid 2:1 Lauric acid 3:1 Acetic acid 3:1 Palmitic acid 3:1 Propionic acid 3:1 tartaric acid 2:1 Butyric acid 3:1 Citric acid 2:1 2-methylbutyric acid 3:1 Malic acid 2:1 3-methylbutyric acid 3:1 oxalic acid 2:1 Valeric acid 3:1 benzoic acid 1:1 Gentisic acid 1:1 Gallic acid 1:1 Phenylacetic acid 3:1 Salicylic acid 1:1 Phthalate 1:1 Picric acid 2:1 Sulfosalicylic acid 1:1 Tannin 1:5 Pectic acid 1:3 Alginic acid 1:2 hydrochloric acid 2:1 Nitric acid 1:1 Benzenesulfonic acid 1:1 Pyruvate 2:1 Glutamate 1:1 Aspartic acid 1:1 sulfuric acid 1:1 Phosphoric acid 1:3

Description: *Recommendation during preparation

The composition (I) may contain a small or trace amount of free nicotine. Usually the amount of free nicotine is less than 10% of the total nicotine (free and bound) in the composition (I), preferably less than 5%, more preferably less than 1%, most preferably less than 0.1%.

The content of nicotine salt in the above composition (I) is usually 0.001% to 25% (wt/wt), but can reach 75% (wt/wt) or higher at the highest, preferably 0.01% to 10% ( wt/wt), more preferably 0.1% to 3% (wt/wt), most preferably 0.5% to 2.0% (wt/wt).

When the above composition (I) is in solution (that is, in a solution state), its pH value is usually neutral or acidic, generally 3 to 6.9, preferably 4 to 6.5, more preferably 4 to 6.0, and most preferably 4.5～5.5. The lower pH of the nicotine salt solution increases the irritation of the solution. The higher pH value of the nicotine salt solution increases the amount of free nicotine in the solution, which greatly increases the choking sensation and the irritation. If the pH of the nicotine salt solution is 6.8, only about 10% of the nicotine in the solution is in free form. At a pH of about 8.8, about 90% of the nicotine in the solution is in the free base form. The pH adjuster is selected from hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, lactic acid, tartaric acid, malic acid, metatartaric acid, acetic acid, adipic acid, fumaric acid, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, citric acid One or more of sodium and potassium citrate are mixed.

The content of the alkali (more alkaline than the nicotine) in the above composition (II) is usually 0.001% to 25% (wt/wt), but can reach 75% (wt/wt) or higher at the highest , Preferably 0.01% to 10% (wt/wt), more preferably 0.1% to 3% (wt/wt), most preferably 0.5% to 2.0% (wt/wt).

When the above composition (II) is in solution (that is, in the state of a solution), the pH value is usually alkaline, generally 7.2-12, preferably 7.5-11, more preferably 8-10, most preferably 8～ 9.

The pharmaceutically acceptable alkali used in the present invention is stronger than the above-mentioned nicotine, and its pKa value is higher than the pKa value of the nicotine, preferably higher than 0.5, more preferably higher than 1, most preferably The height is above 1.5. Since the pKa value of nicotine is 8.02 (at a temperature of 25°C), the pKa value of the aforementioned alkali is greater than 8.02 (at a temperature of 25°C), preferably greater than 8.5, more preferably greater than 9, and most preferably greater than 9.5; The solubility in water or ethanol (at a temperature of 25°C) is usually not less than 10g/kg, preferably not less than 30g/kg, more preferably not less than 50g/kg, and most preferably not less than 100g/kg .

Preferred examples of the pharmaceutically acceptable alkalis stronger than the above-mentioned nicotine for use in the present invention are urea, diarno (2-(dimethylamine) ethanol, pKa9.03), tromethamine (three Hydroxymethylmethylamine, pKa8.1), ethanolamine (pKa10.81), diethylethanolamine (pKa about 10), diethanolamine (pKa11.09), triethanolamine (pKa11.01), diethanol monoisopropanol Amine, dihydroxyethyl tert-butanolamine, ethambutol (ethylenediamine dibutanol), isobutanolamine, dipropanolamine, tripropanolamine, triisopropanolamine, diisopropanolamine , Dibutanolamine, Tributanolamine, Diisobutanolamine, Triisobutanolamine, Dipentanolamine, Tripentanolamine, Diisoamylamine, Triisoamylamine, Dihexanolamine, Trihexanolamine, tromethamine, urethane (urethane), amino monosaccharides or disaccharides, and methyl or ethylated amino monosaccharides or disaccharides (such as deoxystreptamine, deoxyglycosamine ( Such as 2-deoxyglycosamine), deoxyglucosamine (such as 6-deoxy-D-glucosamine), fucosamine and N-ethyl (or form) acyl-fucosamine), galactose Amine (such as D-galactosamine), reduced glucosamine (Glucamine), glucosamine (pKa8.04), meglumine (pKa9.5), meglumine (pKa about 9), neomycamine (or N -Methyl (or acetyl), trehalosamine (diglycosamine), N-methyl (or ethyl) -L-glucosamine (or N-ethyl (or form) acyl-L-glucosamine) Glycosamine), streptobiosamine, chitobiose (β-1,4-disaccharide-glucosamine)), caffeine, pyridoxine/octyl (pKa8.96), pyridoxamine (pKa10.5) , Pyridoxal (pKa8.66), thiamine (pKa9.2), amino acids especially lysine, histidine, arginine, soluble alkaline salts of amino acids (such as lysine, histidine) , Arginine, asparagine, glutamic acid, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, valine, sulfo Alanine, N-glycylglycine, ornithine,), soluble saccharin salt, glycyrrhizic acid normal salt and its basic salt or basic salt, dihydrochalcone normal salt and its basic salt or alkali Salt, creatine, soluble carbonic acid (normal) salt, basic carbonic acid (normal) salt, bicarbonate (pKa10.3), percarbonate, soluble sulfurous acid (normal) salt, thiosulfuric acid ( Normal) salt, phosphoric acid (normal) salt (pKa about 13), hydrogen phosphate (pKa12.67), pyrophosphate (normal) salt and its basic or basic salt, alkali metal or alkaline earth metal soluble basic salt, And mixtures thereof; the above-mentioned soluble salts are preferably ammonium salts and salts formed with alkali metal or alkaline earth metal ions, more preferably sodium, potassium, calcium, magnesium, zinc, and ammonium salts.

More preferred examples of the pharmaceutically acceptable base used in the present invention that are stronger than the above-mentioned nicotine are amino monosaccharides or disaccharides and methyl or ethylated amino monosaccharides or disaccharides (such as deoxystreptamine , Deoxyglucosamine (e.g. 2-deoxyglucosamine), deoxyglucosamine (e.g. 6-deoxy-D-glucosamine), Fucosamine and N-ethyl (or form) acyl-fucose Amine), galactosamine (such as D-galactosamine), reduced glucosamine (Glucamine), glucosamine (pKa8.04), meglumine (pKa9.5), meglumine (pKa about 9), new Mycylamine (or N-ethyl (or form) neomycamine), trehalosamine (diglycosamine), N-methyl (or ethyl) -L-glucosamine (or N-ethyl (or A) Acyl-L-glucosamine), streptobiosamine, chitobiose (β-1,4-disaccharide-glucosamine)), pyridoxine/octyl (pKa8.96), pyridoxamine (pKa10. 5) Pyridoxal (pKa8.66), thiamine (pKa9.2), lysine, histidine, arginine, soluble alkaline salts of amino acids (such as lysine, histidine, Arginine, asparagine, glutamic acid, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, valine, cysteic acid Acid, N-glycylglycine, ornithine,), soluble saccharin salt, glycyrrhizic acid normal salt and its basic salt or basic salt, dihydrochalcone normal salt and its basic salt or basic Salts, creatine salts, and mixtures thereof; the above-mentioned soluble salts are preferably ammonium salts and salts formed with alkali metal or alkaline earth metal ions, and the above-mentioned soluble salts are more preferably sodium, potassium, calcium, magnesium, zinc, ammonium salt. Because they have a better taste, or/and lower irritation.

Table 2 Examples of amino acids preferably used in the present invention

To CAS Registry Number pKa value Water solubility, g/kg Arginine 74-79-3 9.00 182.6 ^a) Asparagine 70-47-3 8.73 25.1 Glutamic acid 56-86-0 9.58 8.61 ^a)b) Glutamine 56-85-9 9.00 42 Glycine 56-40-6 9.58 250.9 Histidine 71-00-1 9.09 43.5 Isoleucine 73-32-5 9.60 34.2 Leucine 61-90-5 9.58 22.0 Lysine 56-97-1 9.16 Very soluble Methionine 63-68-3 9.08 56 Phenylalanine 63-91-2 9.09 27.9 Serine 56-45-1 9.05 50.2 Threonine 72-19-5 8.96 98.1 Valine 72-18-4 9.52 88.5 Cysteic acid 13100-82-8 8.70 Very soluble N-Glycylglycine 556-50-3 8.10 Very soluble Ornithine 70-26-8 8.78 Very soluble

The above data is derived from "Handbook of Chemistry and Physics"("Handbook of Chemistry and Physics", 85th edition, Table 7-1: 20 kinds of standard basic amino acids that constitute proteins, Table 7-2: Amino acids and related important biochemical substances", 85 ^th edition; Table 7-1(“20standard amino acids that are the basic constituents of proteins”) and Table 7-2(“Amino acids and related compounds of biochemical importance”)).

As used herein, the aerosol or aerosol generating agent in the above compositions (I) and (II) means an agent that promotes the formation of aerosol. The aerosol generating agent can promote the formation of aerosol by promoting initial vaporization and/or condensation or sublimation of gas into inhalable solid and/or liquid aerosol. In some embodiments, the aerosol generating agent can improve the delivery of flavour from the aerosol generating material.

Any suitable one or more aerosol generating agents may be included in the above compositions (I) and (II) of the present invention. The suitable aerosol generating agent is selected from pharmaceutically acceptable low boiling point or sublimation point (in the present invention, its definition generally means that the boiling point or sublimation point at 1 atm (1 standard atmosphere) is lower than the temperature of 500°C or 450°C, preferably Ground, 350°C, more preferably 250°C, but not lower than 50°C, preferably not lower than 60°C, more preferably not lower than 70°C, and most preferably not lower than 80°C, the same hereafter, Not otherwise specified), examples of which include, but are not limited to, the following pharmaceutically acceptable additives: low boiling point or sublimation point sugars, such as 1,3-dihydroxyacetone, 1,3-dihydroxyacetone dimer , 2-deoxy-L-ribose, 2-deoxy-D-ribose 2-Deoxy-D-ribose, arabinose, erythrose, erythrulose, D-xylulose, fructose, ribose, xylose, glucose , Sorbose; low boiling point or sublimation point polyols, such as glycerol, xylitol, sorbitol, erythritol; low boiling point or sublimation point glycols, such as propylene glycol, butylene glycol, 1,2-pentanediol , 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol; low boiling point or sublimation point monohydric alcohols, such as monohydric alcohols with C2-C14 atoms (such as ethanol, tert-butanol) Pentanol, lauryl alcohol, myristyl alcohol), menthol, borneol, borneol, isoborneol; low boiling or sublimation point acids, such as lactic acid, adipic acid, benzoic acid, phenylacetic acid, vanillic acid, salicylic acid , Aspirin, C8-C14 fatty acids such as lauric acid, myridine acid; low boiling or sublimation point ethers, aldehydes or ketones, such as vinyl glycerol ethers such as poloxamer (such as poloxamer 105, 124), polyglycerol, Polypropylene glycol, polyethylene glycol (ether), such as diethylene glycol, triethylene glycol, tetraethylene glycol, vanillin, ethyl vanillin, camphor; low boiling point or sublimation point ester, such as polyol ester (glycerol atom number is C1～C8 fatty acid esters (such as glycerol diacetate, glycerol triacetate, butyric acid glyceride), triethylene glycol diacetate), monocarboxylic acid, dicarboxylic acid or polycarboxylic acid ester (Such as fatty alcohol esters with C1-C6 lactic acid atoms, fatty alcohol esters with C1-C6 atoms of C1-C18 fatty acids (such as myristate (such as ethyl myristate and isopropyl myristate) Propyl ester), methyl stearate), diethyl suberate, dimethyl dodecanedioate, dimethyl tetradecanedioate, the number of atoms is C2～C6, and the number of atoms is C1～C6. Fatty alcohol esters (such as triethyl citrate, diethyl malate, diethyl succinate), dodecenyl acetate, benzyl benzoate, phenethyl phenylacetate, ethyl vanillate, propylene carbonate Esters); water; or mixtures thereof.

Examples of particularly preferred aerosol generating agents include, but are not limited to: sorbitol, xylitol, glycerin, ethanol, fatty acid esters with C1 to C4 glycerol atoms, fatty acid esters with C1 to C4 propylene glycol, and poly Glycerin, polypropylene glycol, C2-C6 polybasic acid fatty alcohol esters with C1-C4 atoms, propylene carbonate, and mixtures thereof, such as ethanol, glycerin, propylene glycol, triethylene glycol, butylene glycol (1 ,2-butanediol, 1,3-butanediol, 1,4-butanediol), 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1, 2-Caprylyl glycol, glycerol triacetate, glycerol diacetate formate, glycerol diacetate, glycerol diacetate propionate, glycerol tripropionate, poly-2-hexaglycerin, poly-2-hexapropylene glycol And polydi～hexaethylene glycol, triethylene glycol diacetate, triethyl citrate, diethyl malate, diethyl succinate, propylene carbonate, tetrahydrofuran polyethylene glycol ether (its chemical name As: α-[(tetrahydro-2-furnatyl)methyl]-ω-hydroxy-poly(oxy-1,2-ethylenediyl)), 1,3-dioxan-5-ol, 1 , 3-Dioxolane-4-methanol, 2,2-Dimethyl-1,3-dioxolane-4-methanol, 1,3-propanediol monolactate, 1,3-propanediol monoethyl Ester, 1,3-propanediol monopropyl ester, 1,1-propanediol, 2,2-propanediol, 1,1-propanediol and 1,1-propanediol poly(/condensation) ether, 2,2-propanediol and 2,2-propylene glycol poly(/condensation) ether, 1,1-propylene glycol and 2,2-propylene glycol poly(/condensation) ether, 1,1,1-glycerol and 1,1, Ether formed by poly(/condensation) of 1-glycerol, ether formed by poly(/condensation) of 1,1-propanediol and 1,1,1-glycerol, 2,2-propylene glycol poly(/condensation) Condensed ether and 1,1,1-glycerol poly(/condensation) ether, or their mixture.

When the above compositions (I) and (II) are solutions, the solvent is usually a liquid aerosol generator (at a temperature of 25°C), such as water, ethanol, aliphatic polyols of C3 to C8, and glycerin. C1-C8 fatty acid esters, propylene glycol fatty acid esters with C1-C8 atoms, polyglycerol, polypropylene glycol, C2-C6 polybasic acid fatty alcohol esters with C1-C4 atoms, propylene carbonate, And mixtures thereof, such as water, ethanol, glycerin, propylene glycol, triethylene glycol, butanediol (1,2-butanediol, 1,3-butanediol, 1,4-butanediol), 1,2 -Pentylene glycol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, glycerol triacetate, glycerol diacetate formate, glycerol diacetate, glycerin Diacetate propionate, glycerol tripropionate, polydi-hexaglycerin, polydi-hexapropylene glycol and polyethylene glycol, triethylene glycol diacetate, triethyl citrate, diethyl malate, Diethyl succinate, propylene carbonate, tetrahydrofuran polyethylene glycol ether (its chemical name: α-[(tetrahydro-2-furnatyl)methyl]-ω-hydroxy-poly(oxy-1,2 -Ethylene diyl)), 1,3-dioxan-5-ol, 1,3-dioxolane-4-methanol, 2,2-dimethyl-1,3-dioxolane-4 -Methanol, 1,3-propanediol monolactate, 1,3-propanediol monoethyl ester, 1,3-propanediol monopropyl ester, or mixtures thereof. It can also contain one or more lipids. And it can contain a mixture of the above ingredients.

The above compositions (I) and (II) may include other additives. Other additives can optionally be added to it.

Optional additives include one or more stabilizing additives, such as antioxidants, including vitamin E, namely tocopherol, vitamin C, namely ascorbic acid and its salts, sodium metabisulfite, butylated hydroxytoluene, butylated hydroxyanisole ; And preservatives, including parabens, benzalkonium chloride, chlorobutanol, benzyl alcohol, β-phenylglydol, cetylpyridinium chloride; galate, such as Propyl gallate.

Other optional additives include one or more additives selected from:

-Enhancers (penetration enhancers), such as azone;-vitamins, such as vitamin C and E;-minerals, such as fluoride, especially sodium fluoride, sodium monofluorophosphate and stannous fluoride ;-Deodorants, such as zinc and cyclodextrin;

-Propellants, such as optionally liquefied 1,1,2,2-tetrafluoroethane (HFC-134a) and optionally liquefied 1,1,1,2,3,3,3-heptafluoropropane (HFC -227);-Thickeners (viscosity modifiers), such as polysaccharide compounds.

-Sweeteners, including one or more synthetic sweeteners and/or natural sugars, for example selected from artificial sweeteners, such as saccharin and its sodium and calcium salts, aspartame, acesulfame and its potassium Salt, thaumatin and licorice sweetness;

-Polyols such as sorbitol, xylitol, mannitol and glycerol; monosaccharides, including glucose (also known as dextrose), fructose (also known as levose) and galactose;

-Disaccharides, including sucrose (also known as sucrose), lactose (also known as milk sugar), and maltose (also known as malt sugar);

-Sugar mixtures, including liquid glucose syrups, such as starch hydrolysates mainly containing a mixture of dextrose, maltose, dextrin and water, invert sugar syrups, such as sucrose converted by invertase containing dextrose, fructose and water , High-sugar syrups, such as molasses, honey and malt extract; and mixtures thereof.

-Flavoring and/or aromatic agents, such as essential oils obtained by distillation, solvent extraction or cold pressing of fresh or dried flowers, buds, leaves, stems, fruits, seeds, peel, bark or roots, such as peppermint, spearmint, Eucalyptus, holly, niaouli, cloves, cardamom, cinnamon, bitter almonds, coriander, fennel, ginger, juniper, orange, bitter orange, lemon grapefruit, citrus, bergamot, thyme, anise, and rosemary Fragrant oil

-Natural flavors or fragrances, including flavoring groups naturally derived from fruits, berries, pits, spices, mint, tobacco, cocoa, coffee, tea, vanilla, licorice, caramel, taffy, honey, wine, distilled spirits and beer Diluted liquid of essential oil or concentrate;

-Synthetic flavors and fragrances consisting of: mixed to match, for example, fruits, berries, stones, spices, mint, tobacco, cocoa, coffee, tea, vanilla, licorice, caramel, taffy, honey, wine, distilled spirits Or a mixture of chemical substances in the natural flavor of beer including hydrocarbons, alcohols, aldehydes, esters, ketones, ethers and oxides;

-And their mixture.

The amount (weight) ratio between the above compositions (I) and (II) is not limited, usually 1:100-100:1 (wt/wt), preferably 1:10-10:1 (wt/wt) ), more preferably 1:3 to 3:1 (wt/wt), most preferably 1:1.5 to 1.5:1 (wt/wt).

Method of making the above-mentioned composition (Ⅰ) and (Ⅱ) (aerosol generating material) and using method

The components in the above-mentioned compositions (I) and (II) can be added in any suitable order and mixed until they are uniform. When the above-mentioned compositions (I) and (II) are in liquid form, they can be divided into cartridges or containers with larger volumes, and then added to smoking sets when used later. When the above compositions (I) and (II) are in a solid state, they are mixed until they are uniform and then processed into powders, granules or tablets, which can be divided into cartridges, or directly added to smoking sets when used later.

Term description:

The term "low boiling point or sublimation point" used in the present invention generally means that the boiling point or sublimation point at 1 atm is lower than the temperature 500°C or 450°C, preferably 350°C, more preferably 250°C, but not lower than 50°C. It is preferably not lower than 60°C, more preferably not lower than 70°C, and most preferably not lower than 80°C.

The term "pharmaceutically acceptable" used in the present invention refers to a material that is not biologically or otherwise undesirable, that is, the material can be administered to a (biological) individual, such as a human, without causing any excessive undesirable in the individual Such as toxic biological effects, or will not have excessive harmful interactions with any components in the composition containing it.

The term "additive" as used in the present invention refers to one or more biologically active ingredient carriers that can be mixed with each other without interaction without reducing the stability and/or biological activity of the biologically active ingredient carrier and are suitable for topical use. Or supplementary materials for systemic administration of biologically active ingredients.

The term "about" used in the present invention means that the index value varies within ±30%, preferably within ±20%, within ±10%, most preferably within ±5%, such as about 10, then Represents 7-13, preferably 8-12, more preferably 9-11, most preferably 9.5-10.5.

The term "one type" used in the present invention means to include at least one type, which may be one type, two types or more.

The term "soluble" used in the present invention means that the solubility of a substance in 100 ml of solvent such as water at a temperature of 25°C is not less than 5 g, preferably 10 to 30 g.

Application for treatment, healing and preparation

The electronic cigarette (or aerosol generating system/material) product of the present invention can be used for treatment. The treatment can be selected from the group consisting of reducing the use of tobacco, stopping the use of tobacco, other tobacco use, temporary abstaining from abstaining from use of tobacco, Alzheimer’s disease, Crohn’s disease, Pa Disease or medical indications and weight control of Kingson’s disease, Tourette’s syndrome and ulcerative colitis.

Device

A device (kits, device, equipment, unit) used for aerosolization or vaporization or aerosolization or aerosolization of an electronic cigarette (or aerosol generating system/material) (above), which includes two independent and unconnected devices The atomization subsystem, (aerosolization or vaporization or aerosolization or aerosolization of the above composition (I) and (II) (or two different aerosol-generating materials) respectively), the atomization subsystems respectively include A liquid storage chamber/or accommodating cavity (and its constituent parts), an atomization chamber (and its constituent parts), a mist or smoke channel (and its constituent parts) or guide 1 and the atomizing component or An aerosol-generating component, the liquid storage chamber/or accommodating cavity is directly connected to the atomization chamber or is communicated through a guide member 2, one end of the mist or smoke channel or guide member 1 is in communication with the atomization chamber, and the other end is respectively It communicates with a suction (nozzle) hole, or the other end of the above two mist or smoke channels or guides 1 is near a suction (nozzle) hole ("near" is defined as the distance from the suction (mouth) hole) In the range of 70% of the total length of the channel, preferably 90%, more preferably 95%, and most preferably 99%, it is connected to a suction (nozzle) hole together, or the above two mists or The other end of the smoke channel or guide 1 converges and communicates with a suction (nozzle) hole, the isolation between the two liquid storage chambers/or the accommodating chambers is not connected, the isolation between the two atomization chambers is not connected, the two mists Or the smoke channel or the guide 1 is isolated and not connected (except for the suction (nozzle) hole or the "near" defined above), and the two guides 2 are isolated and not connected. The above-mentioned atomization chamber can be a hollow continuous cavity or a discontinuous cavity, such as the micropores in a material with many micropores (such as non-woven fabrics with many micropores, ceramics, glass, metal, plastics) The above-mentioned guide 2 can be a material containing fine pores (such as non-woven fabric, ceramic, glass, metal, plastic containing fine pores), or a hollow introduction tube; the above-mentioned atomization component includes heating type ( Such as resistance heating type or electromagnetic (oscillation) heating type) or/and vibration type (such as ultrasonic vibration type) or/and compression type atomization assembly. Preferably, a resistance heating type component is applied. When a current is applied to the component, the resistance in the component converts electrical energy into thermal energy for heating the aerosol-forming material. The heating element can be in the form of a wire mesh, a coil, or multiple wires. The heating element may comprise metal or metal alloy. Metal is an excellent conductor of electricity and heat. Suitable metals include, but are not limited to: copper, aluminum, platinum, tungsten, gold, silver, and titanium. Suitable metal alloys include, but are not limited to: nickel-chromium alloys and stainless steel. The aforementioned liquid storage chamber/or containing cavity may be in direct or indirect contact with the liquid, for example, the aforementioned liquid storage room/or containing cavity contains another container such as a cigarette cartridge containing the liquid.

The device used in the present invention also includes a housing, a power supply assembly, and necessary accessories. Further, it can also include cartridges, control components, and (pneumatic) switch components. The casing is provided with a cigarette holder and a vent hole, the suction (mouth) hole is located in the cigarette holder, the vent hole communicates with the air inlet of the atomization chamber, and the outlet hole of the atomization chamber is connected to the mist or smoke channel Or the guide 1 is connected. Preferably, the inner wall of the pharyngeal mouth is provided with multi-level (annular) accommodating cavities, which can prevent the user from not inhaling the e-liquid when smoking the mouthpiece, so that the smoker has a better taste. Preferably, the inner port of the aforementioned air inlet and/or outlet in the atomization cavity is provided with a hole wall protruding from the inner wall of the atomization cavity, so that the smoke oil condensed in the atomization cavity will not directly flow out of the outlet hole It is sucked into the mouth by the user, so that the smoker obtains a better taste, and/or prevents the e-cigarette from flowing out from the air inlet and vent holes to contaminate the internal or external surface of the electronic cigarette.

The above-mentioned device for aerosolization or vaporization or aerosolization or aerosolization of an electronic cigarette (or aerosol generating system/material) (above) can be configured to aerosol-generating material (the above composition (I) and ( Ⅱ)) Heat to a temperature of about 50-500 or 450°C, 100-350°C, 150-350°C, 150-330°C or 180-300°C.

Examples of preferred devices used in the present invention are:

Example 1),

One independent ultrasonic atomizer or compressed atomizer or net atomizer has two atomizer outlets and another independent ultrasonic atomizer or compressed atomizer or net atomizer. An independent and unconnected catheter is connected, the other end of the catheter is connected to two branch pipes of a tee, and the other end of the tee is connected to an inhalation mask that can be placed on the nose and mouth. The mist or smoke in the inhalation mask can be inhaled through the inhalation mask through the nasal cavity or/and the oral cavity. Preferably, the above-mentioned three links are spaced apart from one end of the branch pipe communicating with the inhalation mask that can be placed on the nose and mouth.

Example 2),

An ultrasonic atomizer, compressed atomizer or mesh atomizer includes 2 independent and unconnected atomization subsystems, and the mist outlets of the atomization subsystem are respectively connected by two independent unconnected ducts. , The other end of the catheter is connected with two branch pipes in a tee, and the branch pipe at the other end of the tee is connected with an inhalation mask that can cover the nose and mouth, or one (preferably, The tube separated from each other) is connected to an inhalation mask that can be placed on the nose and mouth, through which the user can inhale the mist or smoke in the inhalation mask through the nasal cavity or/and oral cavity. Preferably, the above-mentioned three links are spaced apart from one end of the branch pipe communicating with the inhalation mask that can be placed on the nose and mouth.

Example 3),

Two e-cigarettes with independent atomization systems are combined for direct oral inhalation together, or after the combination, their mist outlets are respectively connected to two independent and unconnected catheters (such as rubber tubes, silicone tubes) for oral inhalation, Or the other ends of the two independent and unconnected catheters are connected with two branch pipes in a tee, and the branch pipe at the other end of the tee is connected with a catheter that can be used for oral inhalation. The outer diameter of the aforementioned catheter is usually 3mm-12mm, preferably 4mm-6mm. Preferably, the catheter has a large end and a small end, the larger outer diameter is 8mm-12mm, the outer diameter is 2mm-5mm, and the smaller end is used for the mouth.

Example 4), an electronic cigarette device that includes 2 independent and unconnected atomization subsystems (a device for the aerosolization or vaporization or aerosolization or aerosolization of the above-mentioned electronic cigarette (or aerosol generating system/material) (kits, device, equipment, unit)), such as:

Example 4-1),

An electronic cigarette (a device) (a device (kits, device, equipment, unit) used for the aerosolization or vaporization or aerosolization or aerosolization of the electronic cigarette (or aerosol generating system/material) mentioned above), It includes a cigarette-shaped cavity housing (4), a power supply (2), a cigarette cartridge (3) and a cigarette stick accessory. The housing is sequentially provided with the power supply (2), one Pneumatic switch (7), high-frequency generator (8), a magnetostrictive vibrator (9) and an electromagnetic induction heater (liquid storage chamber/or accommodating chamber) separated by two non-communicating chambers ( 10) or said a pneumatic switch (7), a power supply (2), a high-frequency generator (8), a magnetostrictive vibrator (9) and two chambers (liquid storage The electromagnetic induction heater (10) of the chamber/or containing cavity), wherein the high-frequency generator (8) is connected to the magnetostrictive vibrator (9) and the electromagnetic induction heater (10) through wires. Connect with pneumatic switch (7);

A light emitting diode (6) is provided at the front end of the housing (4), which is respectively connected to the pneumatic switch (7) and the power source (2) through wires;

The rear end of the shell (4) is connected with the cartridge (3), and two compartments (liquid storage chamber/or containing Cavity) (31);

The vapor or smoke channels in the electronic cigarette (the cigarette rod attachment) are spaced apart and not communicated with each other. (As shown in Figure 1-1 and 3)

Preferably, the above electronic cigarette further includes a cigarette cap (1), which is arranged at the front end of the light emitting diode (6) and covers the light emitting diode (6) inside.

Preferably, the power source (2) described in the above electronic cigarette is a rechargeable battery, which has a charging positive electrode contact point (21) and a negative electrode contact point (22).

Preferably, the magnetostrictive vibrator (9) described in the above electronic cigarette includes: a magnetostrictive rod (93) with a permanent magnet (91) provided at both ends of the magnetostrictive vibrator. A drive coil (92) is wound on the outside of the telescopic rod (93) and the two permanent magnets (91), and a vibration sensor (94) is arranged on the permanent magnet (91) and the electromagnetic induction heater ( 10) Between. (As shown in Figure 1-2)

Preferably, the electromagnetic induction heater (10) described in the above electronic cigarette includes: a vibrating plate (101) is fixedly connected to the housing (4) by an external thread thereon, and the lower part is correspondingly provided with A stainless steel tube (104) with two cavities (liquid storage chamber/or accommodating cavity) spaced apart from each other, and inside the two cavities (liquid storage chamber/or accommodating cavity) of the stainless steel tube (104) Nickel mesh wires (103) are respectively installed, and an induction coil (102) is arranged between the stainless steel tube (104) and the housing (4). (As shown in Figure 1-2)

Preferably, the pneumatic switch (7) described in the above electronic cigarette includes: an upper clip body (71) and a lower clip body (74) butted together, wherein the upper clip body (71) And the butt joints of the lower clip body (74) are respectively provided with grooves, and the outer edge of a silicone bladder (73) is arranged in the grooves, and the silicone bladder (73) has a central hole and a magnet (72) Installed in the central hole of the silicone bladder (73), the lower clip body (74) is provided with a vent hole, the upper clip body (71) is provided with a circuit board, the upper clip body (71) and the outer side of the lower clamp body (74) are provided with wire grooves for placing the wires of the circuit board. (As shown in Figure 1-4)

Preferably, the silicone bladder (73) in the electronic cigarette is provided with air slits or pores.

Preferably, the circuit board described in the electronic cigarette is provided with a human body clutter sensor (75), a data processor (76), a master control output circuit (77), and an amplified output circuit connected in series in sequence. (78) and an over-temperature, over-current and over-discharge protection circuit (79), wherein the amplifying output circuit (78) and over-temperature, over-current and over-discharge protection circuit (79) are connected to an ultrasonic atomizer (70) . (As shown in Figure 1-5)

Preferably, the cartridge (3) described in the above electronic cigarette includes a casing (33) on which a positioning boss (35) is provided, and the casing is sequentially arranged with spaced apart and non-communicating The bayonet (32), the two smoke liquid return chambers (34) which are separated and not communicated, and the two liquid storage chambers/or the containing chambers (31) which are separated and not communicated. The outer end of the housing (33) is provided There is a cotton screen (36) which is separated and is not connected to prevent the smoke liquid from being sucked into the mouth of the user. (As shown in Figure 1-6)

Example 4-2),

An electronic cigarette (a device) (a device (kits, device, equipment, unit) used for the aerosolization or vaporization or aerosolization or aerosolization of the electronic cigarette (or aerosol generating system/material) mentioned above), It is characterized in that the device includes an outer casing, a cigarette holder, necessary accessories and an ultrasonic atomization device; the outer casing and the cigarette holder have two isolated and unconnected mist or smoke channels, one end of which is communicated with the air outlet on the cigarette holder, The other end is communicated with the aerosol outlet in the above-mentioned ultrasonic atomization device; the ultrasonic atomization device includes an inner casing (10), a power supply (12), a liquid storage part (liquid storage chamber/or accommodation cavity) (14), A mesh member (20) and a vibration source (30), a liquid storage portion (liquid storage chamber/or accommodation cavity) (14) is formed in the housing (10), and the liquid storage portion (liquid storage chamber/or The accommodating cavity) (14) (middle) is separated from each other, and the upper end is provided with an openable and closable liquid filling port (for storing liquid) and an aerosol outlet, the aerosol outlet and the mist communicating with it The vapor or smoke channels are separated (in the middle) and are not connected to each other. The mesh member (20) is embedded at the outlet of the aerosol, and the mesh member (20) has a plurality of fine holes (21). Porous mesh structure, the vibration source (30) is connected to the mesh member (20), the vibration source (30) is electrically connected to the power source (12), and the vibration source (30) can be Generate vibrations and drive the mesh member (20) to vibrate to vibrate and atomize the liquid near the mesh member (20); the fine holes (21) penetrate the mesh member (20) to make the liquid mist The transformed smoke can flow out along the micropores 21, the mesh member (20) is electrically connected to the power source (12), and the mesh member (20) can generate heat after being energized and cause the mesh member ( 20) The nearby liquid is heated and atomized. (As shown in Figure 2-1, 2)

Preferably, in the ultrasonic atomization device, the vibration source (30) is at least partially located in the liquid storage portion (14), and the end surface of one end of the vibration source (30) is in contact with the mesh The member (20) is connected.

Preferably, in the ultrasonic atomization device, the vibration source (30) is located between the power source (12) and the liquid storage portion (14), and one end of the vibration source (30) extends into Inside the liquid storage part (14).

Preferably, the ultrasonic atomization device, wherein the ultrasonic atomization device is used for electronic cigarettes, and the housing (10) is provided with a partition (18) hermetically connected with the housing (10) , The partition (18) seals and forms the bottom of the liquid storage portion (14), and one end of the vibration source (30) passes upwards through the partition (18) and extends into the liquid storage portion (14). )Inside.

Preferably, in the ultrasonic atomization device, a cover (24) is provided between the periphery of the mesh member (20) and the aerosol outlet of the liquid storage portion (14), and the mesh member (20) It is sealed with the housing (10) by the cover liner (24), and the periphery of the mesh member (20) abuts against the cover liner (24), so that the mesh member (20) can be kept in place even when vibrated Inside the cover lining (24).

Preferably, in the ultrasonic atomization device, the longitudinal section of the liquid storage portion (14) is in a concave shape, and the center of the liquid storage portion (liquid storage chamber/or accommodation cavity) (14) is formed (middle ) Isolate the two aerosol channels (16) that are not communicating with each other. One end of the micropores (21) of the mesh member (20) is in communication with the liquid storage portion (14), and the other end is connected with the aerosol channel ( 16) Connectivity.

Preferably, in the ultrasonic atomization device, the mesh member (20) is a flat plate structure, and the fine holes (21) of the mesh member (20) are arranged in a honeycomb shape through the ribs (23). The micropore (21) has a large pore diameter at both ends and a small middle pore diameter, or the micropore (21) has a large pore diameter at one end and a small pore diameter at the other end, wherein when the micropore (21) has a diameter at one end Larger and smaller pore size at the other end, the end with larger pore size is the liquid inlet end communicating with the inside of the liquid storage part (14), and the end with the smaller pore size is the aerosol outlet end.

Preferably, in the ultrasonic atomization device, the mesh member (20) further includes a metal mesh, and the metal mesh includes two layers, which are the top metal mesh and the metal mesh on the top of the mesh member (20). The bottom metal mesh is arranged at the bottom of the mesh member (20), and the ribs (23) are arranged at intervals between the bottom metal mesh and the top metal mesh, and are electrically connected to the bottom metal mesh and the top metal mesh.

Preferably, in the ultrasonic atomization device, the mesh member (20) is made of conductive anti-corrosion material.

Example 4-3),

An integrated electronic cigarette (set) with an oil cup (a type of electronic cigarette (or aerosol generating system/material) used for aerosolization or vaporization or aerosolization or aerosolization of the above electronic cigarette (or aerosol generating system/material) with an oil cup A device (kits, device, equipment, unit)), including a housing (1) and a control component (2), a battery (3) and an atomizer (4) arranged in the housing (1), the control component (2) Electrically connected to the heating wire (41) of the battery (3) and the atomizer (4), characterized in that: the casing (1) is also provided with an oil cup (storage) for containing smoke liquid The liquid chamber/or containing cavity) (5), the atomizer (4) and the oil cup (liquid storage chamber/or containing cavity) (5) are arranged adjacently, and the oil cup (5) is adjacent to the atomizer ( 4) One end is provided with an e-liquid outlet (51), and the e-liquid outlet (51) is packaged with a material with micropores (such as non-woven fabric with micropores, ceramics, glass, metal, plastic) preferably Non-woven fabric (52), the heating filaments (41) of the atomizer (4) are arranged in close contact with the material with micropores (preferably non-woven fabric (52)), and the atomizer (4) And the oil cup (liquid storage chamber/or containment chamber) (5) has two chambers (liquid storage chamber/or containment chamber) which are separated from each other, and the e-liquid outlet (51) and its communicating The fog or smoke channel (middle) is isolated and not connected to each other. (As shown in Figure 3-1)

Preferably, the caliber of the e-liquid outlet (51) in the electronic cigarette is the same as the caliber of the oil cup (5).

Preferably, one end of the housing (1) in the above-mentioned electronic cigarette is provided with (in the middle) two channels which are not connected to each other but smoke can pass through respectively, and the above-mentioned channel openings (ie nozzle holes) are provided. The cigarette holder cover (11) of the housing (1) is provided with a lamp cover (12) with an LED lamp at the other end of the housing (1), the control assembly (2) is fixed in the lamp cover (12), and the control assembly (2) Including control circuit board and control switch.

Preferably, a first air inlet (121) is provided on the side of the lamp cover (12) in the above electronic cigarette, and the control switch of the control assembly (2) is an inhalation automatic switch.

Preferably, the atomizer (4) in the above-mentioned electronic cigarette includes an oil-separating silicone seat (42) and a (middle) isolation connecting pipe (43) through which the smoke is not communicated with each other. The oil silicone seat (42) is in interference fit with the housing (1), one end of the connecting pipe (43) is in contact with the grease-proof silicone seat (42), and the other end of the connecting pipe (43) is in contact with the smoke liquid On the material with micropores (preferably non-woven fabric (52)) on the end face of the outlet (51), a glass fiber rope (44) is respectively arranged on the two cavities separated by the connecting pipe (43), and the heating wire (41) ) Is wound around the glass fiber rope (44), and the oil-separating silicone seat (42) is provided with two air inlets (or (in the middle) isolation and non-communication) (421) separately isolated from the connecting pipe (43) The two chambers are communicated, and the air holes (421) are respectively communicated with the first air inlet hole (121) and a suction nozzle hole on the cigarette holder cover (11). (As shown in Figure 3-1)

Example 4-4),

An electronic cigarette device (/tool) (a device used for the aerosolization or vaporization or aerosolization or aerosolization of the above-mentioned electronic cigarette (or aerosol generating system/material) (kits, device, equipment, unit) ), the device (/smoker) includes (upper and lower) housings, power supply components, necessary accessories and 2 independent and unconnected atomization subsystems; the lower housing (which is a rectangular parallelepiped) contains power supply components, Atomization subsystem, two isolated and incommunicable mist or smoke channels, one end of the mist or smoke channel is in communication with the above-mentioned atomization subsystem, and the other end is in communication with the mist or smoke channel in the upper casing described below; The upper shell is a cigarette holder, which (in the shape of two oblique sides (preferably arc-shaped),) the long side is connected to the lower shell, and the short side has two air outlets (the trapezoidal body), which has One end of the two isolated and incommunicable mist or smoke passages is communicated with the above-mentioned air outlet, and the other end is communicated with the mist or smoke passage in the lower casing. Preferably, the edges (/sides) or/and corners of the upper shell and the lower shell are rounded. Preferably, the suction end of the mouthpiece of the upper shell is extended to meet the needs of smoking. The above-mentioned upper shell mouthpiece extension may be in a shape of a cylinder, square prism, prismatic, or hammer without being limited to science.

The above-mentioned independent atomization subsystems respectively include a liquid storage chamber/or accommodating cavity (and its constituent parts), an atomization chamber (and its constituent parts), a mist or smoke channel (and its constituent parts) or guide member 1 And the atomization component, the liquid storage chamber/or the accommodating cavity and the atomization chamber are directly communicated or communicated through the guide member 2, and the mist or smoke channel or the guide member 1 is the mist in the upper and lower shells. Vapor or smoke channel, the isolation between the two liquid storage chambers/or containing chambers is not connected, the isolation between the two atomization chambers is not connected, the isolation between the two guides 2 is not connected, the two vapor or smoke channels or the guide 1 The isolation is not connected.

The above-mentioned compositions (I) and (II) are respectively placed in the two isolated and unconnected liquid storage chambers/or accommodating chambers (or chambers), or the above-mentioned compositions (I) and (II) are respectively preset in The glass, ceramic, metal and other containers are placed together with the above-mentioned container in the above-mentioned two isolated liquid storage chambers/or containing chambers (or chambers).

The main characteristics and advantages of the invention (industrial applicability):

1) Compared with current nicotine replacement products, this product can better deliver or "promote" nicotine, and better provide a positive recipient nicotine effect, and

2) Better alleviate addiction, and better control addiction, and

3) Higher nicotine bioavailability (bioavailability);

4) The performance is relatively smooth and supple when used, the throat and/or oral properties are good, the user is not easy to produce "resistance", the satisfaction and comfort are better, the choking sensation is low, and the irritation is less;

5) Good stability, not easy to be oxidized and degraded, and not easy to volatilize and lose.

In short, the present invention almost inherits all the advantages of nicotine salt and free nicotine, and almost overcomes all the disadvantages of nicotine salt and free nicotine.

Description of the drawings:

1. Figure 1-1 is a structural diagram of example 4-1 of electronic cigarettes;

2. Figure 1-2 is a schematic diagram of the structure of the magnetostrictive ultrasonic vibrator and electromagnetic induction heater of e-cigarette example 4-1;

3. Figure 1-3 is a schematic diagram of the control circuit of the electronic cigarette example 4-1;

4. Figure 1-4 is a schematic diagram of the pneumatic switch structure of the electronic cigarette example 4-1;

5. Figure 1-5 is a schematic diagram of the theme structure of the circuit board of the electronic cigarette example 4-1;

6. Figure 1-6 is a schematic diagram of the structure of the electronic cigarette case 4-1 cartridge.

7. Figure 2-1 is a schematic diagram of the structure of the ultrasonic atomization device in Example 4-2 of the electronic cigarette;

8. Figure 2-2 is the working flow chart of the ultrasonic atomization device in Example 4-2 of the electronic cigarette.

9. Figure 3-1 is a schematic cross-sectional structure diagram of Example 4-3 of the electronic cigarette.

Example

Example 1

Nicotine salt solution: nicotine maleate, concentration: 0.08%, solvent: water and butanediol (volume ratio 9:1), pH value: 5.2, (add to) total: 100ml;

Alkaline solution: potassium leucine, concentration: 12.5%, solvent: water, total amount: 100 ml.

Atomization device: The mist outlet of an independent ultrasonic atomizer and the mist outlet of another independent ultrasonic atomizer are respectively connected by two independent and unconnected pipes. The other end of the pipe is connected to the The two branch pipes are connected, and the branch pipe at the other end of the tee is connected with an inhalation mask that can be placed on the nose and mouth. The user can inhale the mist in the inhalation mask through the nasal cavity or/and oral cavity through the inhalation mask For steam or smoke, the above-mentioned three links are spaced apart and not communicated with one end of the branch pipe that communicates with the inhalation mask that can be placed on the nose and mouth. The above-mentioned ultrasonic atomizer is Yuehua ultrasonic atomizer (model: WH-2000), and the atomization speed is about 2ml/min.

Example 2

Nicotine salt solution: galactose diacid nicotine salt, concentration: 1.5%, solvent: water and ethanol (volume ratio 8:2), pH value: 3.2, (add to) total: 100ml;

Alkaline solution: fucosamine, concentration: 4.5%, solvent: water and glycerin (volume ratio 8:2), (add to) total amount: 100ml.

Atomization device: The mist outlet of an independent compression atomizer and the mist outlet of another independent compression atomizer are respectively connected by two independent unconnected pipes, and the other end of the pipe is connected with a three-way The two branch pipes in the three links are connected, and the branch pipe at the other end of the tee is connected with an inhalation mask that can be placed on the nose and mouth. The user can inhale the inhalation mask through the nasal cavity or/and oral cavity The above-mentioned three links are separated from one end of the branch pipe that communicates with the inhalation mask that can be placed on the nose and mouth. The above-mentioned ultrasonic atomizer is: a fish-leap compression atomizer (model: 403H), and the atomization speed is about 0.25 ml/min.

Example 3

Nicotine salt solution: nicotine malate, concentration: 0.5%, solvent: water and propylene glycol (volume ratio 7:3), pH value: 5.6, (add to) total: 100ml;

Alkaline solution: sodium ornithine, concentration: 17.5%, solvent: water, total amount: 100 ml.

Atomization device: The mist outlet of an independent compression atomizer and the mist outlet of another independent compression atomizer are respectively connected by two independent unconnected pipes, and the other end of the pipe is connected with a three-way The two branch pipes in the three links are connected, and the branch pipe at the other end of the tee is connected with an inhalation mask that can be placed on the nose and mouth. The user can inhale the inhalation mask through the nasal cavity or/and oral cavity The above-mentioned three links are separated from one end of the branch pipe that communicates with the inhalation mask that can be placed on the nose and mouth. The above-mentioned ultrasonic atomizer is: Omron compression atomizer (model: NE-C25S), and the atomization speed is about 0.25 ml/min.

Example 4

Nicotine salt solution: nicotine oxalate, concentration: 0.7%, solvent: water and glycerin (volume ratio 7.5: 2.5), pH value: 6.2, (add to) total: 100ml;

Alkaline solution: sodium propionate water, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 6:4), (add to) total amount: 100ml.

Atomization device: The mist outlet of an independent compression atomizer and the mist outlet of another independent compression atomizer are respectively connected by two independent unconnected pipes, and the other end of the pipe is connected with a three-way The two branch pipes in the three links are connected, and the branch pipe at the other end of the tee is connected with an inhalation mask that can be placed on the nose and mouth. The user can inhale the inhalation mask through the nasal cavity or/and oral cavity The above-mentioned three links are separated from one end of the branch pipe that communicates with the inhalation mask that can be placed on the nose and mouth. The above-mentioned ultrasonic atomizer is an Omron compression atomizer (model: NE-C28), and the atomization speed is about 0.25 ml/min.

Example 5

Nicotine salt solution: succinic acid (succinic acid) nicotine salt, concentration: 3.5%, solvent: water and glycerol acetate (volume ratio 9:1), pH value: 5.2, (add to) total: 100ml ；

Alkaline solution: calcium gluconate, concentration: 0.5%, solvent: water and glycerin (volume ratio 7:3), (add to) total amount: 100ml.

Atomization device: The mist outlet of an independent net atomizer and the mist outlet of another independent net atomizer are respectively connected by two independent and unconnected pipes, and the other end of the pipe is connected to a tee The two branch pipes in the three links are connected, and the branch pipe at the other end of the tee is connected with an inhalation mask that can be placed on the nose and mouth. The user can inhale the inhalation mask through the nasal cavity or/and oral cavity The above-mentioned three links are separated from one end of the branch pipe that communicates with the inhalation mask that can be placed on the nose and mouth. The above-mentioned ultrasonic atomizer is a fish-leap-net atomizer (model: M-102 or HL100A), and the atomization speed is about 0.2ml/min.

Example 6

Nicotine salt solution: nicotine salt of ketoglutarate, concentration: 4.5%, solvent: water and polyethylene glycol (volume ratio 8.5: 1.5), pH value: 4.5, (add to) total: 100ml;

Alkaline solution: sodium pyrophosphate, concentration: 1.5%, solvent: water and butanediol (volume ratio 9.5:0.5), (add to) total amount: 100ml.

Atomization device: The mist outlet of an independent compression atomizer and the mist outlet of another independent compression atomizer are respectively connected by two independent unconnected pipes, and the other end of the pipe is connected with a three-way The two branch pipes in the three links are connected, and the branch pipe at the other end of the tee is connected with an inhalation mask that can be placed on the nose and mouth. The user can inhale the inhalation mask through the nasal cavity or/and oral cavity The above-mentioned three links are separated from one end of the branch pipe that communicates with the inhalation mask that can be placed on the nose and mouth. The above-mentioned ultrasonic atomizer is a Philips compressed atomizer (model: CN-B-0103), and the atomization speed is about 0.2ml/min.

Example 7

Nicotine salt solution: nicotine citrate, concentration: 1.5%, solvent: water and glycerol triacetate (volume ratio 8.5: 1.5), pH value: 5.3, (add to) total: 10ml;

Alkaline solution: sodium hydrogen phosphate, concentration: 0.8%, solvent: water and propylene glycol (volume ratio 8.5: 1.5), (add to) total amount: 1000 ml.

Atomization device: The mist outlet of an independent net atomizer and the mist outlet of another independent net atomizer are respectively connected by two independent and unconnected pipes, and the other end of the pipe is connected to a tee The two branch pipes in the three links are connected, and the branch pipe at the other end of the tee is connected with an inhalation mask that can be placed on the nose and mouth. The user can inhale the inhalation mask through the nasal cavity or/and oral cavity The above-mentioned three links are separated from one end of the branch pipe that communicates with the inhalation mask that can be placed on the nose and mouth. The above-mentioned ultrasonic atomizer is a Raffles mesh atomizer (model: mini air 360+), and the atomization speed is about 0.8ml/min.

Example 8

Nicotine salt solution: nicotine tartrate, concentration: 2.5%, solvent: water, propylene glycol, polydiglycerol (volume ratio 1.5:6.5:2), pH value: 6.5, (add to) total: 100ml;

Alkaline solution: sodium carbonate, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking device, the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the invention patent CN201410223508.8 or a commercially available electronic smoking set (such as MOTI brand, TENSO brand, Huali door brand, HOPESON brand, the same hereafter).

Example 9

Nicotine salt solution: nicotine acetate, concentration: 2.5%, solvent: water and propylene carbonate (volume ratio 1.5:8.5), pH value: 5.5, (add to) total: 100ml;

Alkaline solution: sodium phosphate, concentration: 1.2%, solvent: water and propyl glycerol diacetate (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the invention patent CN201410371441.2 or a commercially available electronic smoking set.

Example 10

Nicotine salt solution: nicotine butyrate salt, concentration: 0.5%, solvent: water, propylene glycol, triacetin (volume ratio 1.5:6.5:2), pH value: 5.2, (add to) total: 1000ml ；

Alkaline solution: trisodium glycyrrhizinate, concentration: 0.5%, solvent: water, propylene glycol, glycerin (volume ratio 1:7.5:1.5), (add to) total amount: 10ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201320043282.4 or a commercially available electronic smoking set.

Example 11

Nicotine salt solution: nicotine lactate, concentration: 2.5%, solvent: water, propylene glycol, polytriglycerol (volume ratio 1:7:2), pH value: 4.2, (add to) total: 100ml;

Alkaline solution: sodium saccharin, concentration: 2.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201390000190.6 or a commercially available electronic smoking set.

Example 12

Nicotine salt solution: acrylic acid nicotine salt, concentration: 1.5%, solvent: water and propylene carbonate (volume ratio 1.5:8.5), pH value: 6.5, (add to) total amount: 100ml;

Alkaline solution: potassium cysteic acid, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201390000289.6 or a commercially available electronic smoking set.

Example 13

Nicotine salt solution: nicotine gluconate salt, concentration: 1.5%, solvent: water, propylene glycol, polyethylene glycol 200 (volume ratio 1:8:1), pH value: 5.3, (add to) total: 10ml ；

Alkaline solution: ammonium valine, concentration: 3.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201320734533.3 or a commercially available electronic smoking set.

Example 14

Nicotine salt solution: L-lactate nicotine salt, concentration: 0.5%, solvent: water and propylene carbonate (volume ratio 1.5:8.5), pH value: 4.2, (add to) total: 100ml;

Alkaline solution: arginine, concentration: 4.5%, solvent: water and propylene glycol, glyceryl caprylate (volume ratio 1.5:6.5:2), (add to) total: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201320734377.0 or a commercially available electronic smoking set.

Example 15

Nicotine salt solution: nicotine salt of alpha-hydroxycaproic acid, concentration: 1.5%, solvent: water, propylene glycol, glycerin (volume ratio 1.5: 7.5: 1), pH value: 5.2, (add to) total: 100 ml;

Alkaline solution: triethanolamine, concentration: 1.5%, solvent: propylene glycol, (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201390000294.7 or a commercially available electronic smoking set.

Example 16

Nicotine salt solution: nicotine caprylate salt, concentration: 4.5%, solvent: water, propylene glycol, polyhexaglycerol (volume ratio 1.5:7.5:1), pH value: 5.6, (add to) total: 100ml;

Alkaline solution: sodium glycinate, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201390000291.3 or a commercially available electronic smoking set.

Example 17

Nicotine salt solution: nicotine benzoate, concentration: 2.5%, solvent: water, propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 200ml;

Alkaline solution: lysine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5: 8.5), (add to) total amount: 100 ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the invention patent CN201410371441.2 or a commercially available electronic smoking set.

Example 18

Nicotine salt solution: nicotine salicylate, concentration: 0.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), pH value: 6.4, (add to) total: 100ml;

Alkaline solution: thiamine, concentration: 0.5%, solvent: water and propylene glycol, glycerol acetate (volume ratio 1.5:6.5:2), (add to) total: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the invention patent CN200710121524.6 or a commercially available electronic smoking set.

Example 19

Nicotine salt solution: mandelic acid (mandelic acid) nicotine salt, concentration: 3.5%, solvent: water, propylene glycol, polyethylene glycol 300 (volume ratio 1.5: 7.5: 1), pH value: 5.5, (add to ) Total amount: 100ml;

Alkaline solution: sodium phenylalanine, concentration: 1.5%, solvent: water, propylene glycol, glycerin (volume ratio 1.5:6.5:2), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201621239037.0 or a commercially available electronic smoking set.

Example 20

Nicotine salt solution: Protocatechuic acid (3,4-dihydroxybenzoic acid) nicotine salt, concentration: 6.5%, solvent: water and propylene glycol, diethyl malate (volume ratio 1.5:8.0:0.5), pH Value: 5.2, (add to) total amount: 100ml;

Alkaline solution: pyridoxamine, concentration: 2.5%, solvent: water and propylene glycol, glyceryl caproate (volume ratio 1.5:8.0:0.5), (add to) total: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201720429415.X or a commercially available electronic smoking set.

Example 21

Nicotine salt solution: nicotine glucuronic acid salt, concentration: 5.5%, solvent: water and propylene glycol, diethyl succinate (volume ratio 1.5:8.0:0.5), pH value: 4.5, (add to) total : 100ml;

Alkaline solution: neomycamine, concentration: 2.5%, solvent: water, propylene glycol, glycerin (volume ratio 1.5:6.5:2), (add to) total amount: 100ml.

Atomization device: Device example 4-1 in the specification (ie the device shown in Figures 1-1 to 6).

Example 22

Nicotine salt solution: nicotine ascorbate salt, concentration: 9.5%, solvent: water and propylene carbonate (volume ratio 1.5:8.5), pH value: 5.4, (add to) total: 100ml;

Alkaline solution: pyridoxine, concentration: 2.5%, solvent: ethanol and propylene glycol (volume ratio 1:9), (add to) total amount: 100ml.

Atomization device: Device example 4-1 in the specification (ie the device shown in Figures 1-1 to 6).

Example 23

Nicotine salt solution: Angelica acid ((Z)-2-methyl-2-butenoic acid) nicotine salt, concentration: 3.5%, solvent: water, propylene glycol, propylene carbonate (volume ratio 1.5:6.5:2) , PH value: 6.5, (add to) total amount: 100ml;

Alkaline solution: meglumine, concentration: 1%, solvent: water and glycerol triacetate (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: Device example 4-1 in the specification (ie the device shown in Figures 1-1 to 6).

Example 24

Nicotine salt solution: carboxyglutamate nicotine salt, concentration: 4.5%, solvent: water and propylene glycol (volume ratio 2:8), pH value: 6.2, (add to) total: 100ml;

Alkaline solution: galactosamine, concentration: 2.5%, solvent: water, propylene glycol, glycerin (volume ratio 1.5: 7.5: 1), (add to) total amount: 100 ml.

Atomization device: Device example 4-1 in the specification (ie the device shown in Figures 1-1 to 6).

Example 25

Nicotine salt solution: nicotine salt of glycyrrhizinate, concentration: 3.5%, solvent: water, propylene glycol, glyceryl caprylate (volume ratio 1.5:7.5:1), pH value: 6.1, (add to) total: 100ml;

Alkaline solution: caffeine, concentration: 0.5%, solvent: ethanol and propylene glycol (volume ratio 0.5:9.5), (add to) total amount: 100ml.

Atomization device: Device example 4-2 in the specification (ie the device shown in Figures 2-1 to 2).

Example 26

Nicotine salt solution: aspartic acid nicotine salt, concentration: 3.5%, solvent: water and propylene glycol, triacetin (volume ratio 1.5:6.5:2), pH value: 5.7, (add to) total : 100ml;

Alkaline solution: 2-deoxyglycosamine, concentration: 4.5%, solvent: water, propylene glycol, glycerin (volume ratio 1.5:7.0:1.5), (add to) total amount: 100ml.

Atomization device: Device example 4-3 in the specification (ie the device shown in Figure 3-1).

Example 27

Nicotine salt solution: inosinic acid nicotine salt, concentration: 2.5%, solvent: water, propylene glycol, glyceryl caprylate (volume ratio 1.5: 7.5: 1), pH value: 6.2, (add to) total: 100ml ；

Alkaline solution: tributanolamine, concentration: 0.8%, solvent: propylene glycol, total amount (to be added): 100ml.

Atomization device: Device example 4-3 in the specification (ie the device shown in Figure 3-1).

Example 28

Nicotine salt solution: nicotine cinnamic acid salt, concentration: 2.5%, solvent: water, propylene glycol, propylene carbonate (volume ratio 1.5:6.5:2), pH value: 5.2, (add to) total: 100ml;

Alkaline solution: Glucosamine, concentration: 0.5%, solvent: water and poloxamer 124, (add to) total amount: 100ml.

Atomization device: Device example 4-3 in the specification (ie the device shown in Figure 3-1).

Example 29

Nicotine salt solution: nicotine hydrochloride salt, concentration: 2.5%, solvent: water and propylene glycol, glycerol tripropionate (volume ratio 1.5:7.5:1), pH value: 4.8, (add to) total: 100ml;

Alkaline solution: N-acetyl-D-glucosamine, concentration: 1.0%, solvent: benzyl benzoate and ethanol (volume ratio 8.5: 1.5), (add to) total amount: 100 ml.

Atomization device: Device example 4-3 in the specification (ie the device shown in Figure 3-1).

Example 30

Nicotine salt solution: nicotine sulfate salt, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5: 8.5), pH value: 4.2, total (add to): 100ml; propylene glycol

Alkaline solution: dipropanolamine, concentration: 0.5%, solvent: dodecenyl acetate and ethanol (volume ratio 8.5: 1.5), (add to) total amount: 100 ml.

Atomization device: device example 4-4 in the specification, the lower and upper shells are set according to device example 4-4 in the specification, according to the utility model patent CN206079032U or CN201420045870.6 disclosed power supply components, atomization subsystem, accessories, etc. , There are two sets of the same but independent and unconnected devices containing the power components, atomization subsystems, accessories and other components disclosed in the above patent (all the same as the patent); or device example 4-1 in the specification (That is, the device shown in Figures 1-1 to 6).

Example 31

Nicotine salt mixture: nicotine phosphate, content: 1.5%, diluent or aerosol generator: camphor, (add to) total: 100g;

Alkaline solution: ethanolamine, concentration: 0.5%, solvent: ethyl vanillate and ethanol (volume ratio 8.5: 1.5), (add to) total amount: 100 ml.

Atomization device: Device example 4-2 in the specification (ie the device shown in Figures 2-1 to 2).

Example 32

Nicotine salt solution: nicotine besylate, concentration: 4.5%, solvent: water, propylene glycol, propylene carbonate (volume ratio 1.5:6.5:2), pH value: 5.6, (add to) total: 100ml;

Alkaline solution: tromethamine, concentration: 2.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: device example 4-4 in the specification, the lower and upper shells are set according to device example 4-4 in the specification, according to the utility model patent CN206079032U or CN201420045870.6 disclosed power supply components, atomization subsystem, accessories, etc. , There are two sets of the same but independent and unconnected devices containing the power components, atomization subsystems, accessories and other components disclosed in the above patent (all the same as the patent); or device example 4-1 in the specification (That is, the device shown in Figures 1-1 to 6).

Example 33

Nicotine salt mixture: nicotine metasulfite, content: 2.5%, diluent or aerosol generator: vanillic acid, (add to) total: 100g;

Alkaline solution: diethanolamine, concentration: 0.8%, solvent: triethyl citrate, (add to) total amount: 100ml.

Atomization device: device example 4-4 in the specification, the lower and upper shells are set according to device example 4-4 in the specification, according to the power components, atomization subsystems, accessories, etc. disclosed in the invention patent CN206079032U or CN200910080147.5, There are two sets of identical but independent devices containing the power supply components, atomization subsystems, and accessories disclosed in the above-mentioned patent (all the same as those in the patent); or the device example 4-1 in the specification ( That is, the device shown in Figures 1-1 to 6).

Example 34

Nicotine salt solution: nicotine malate, concentration: 2.5%, solvent: water and propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: sodium glutamate, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the invention patent CN201410371441.2 or a commercially available electronic smoking set.

Example 35

Nicotine salt solution: nicotine salt of licorice diacid, concentration: 2.5%, solvent: water, propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: meglumine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: the same as in Example 34.

Example 36

Nicotine salt solution: nicotine tartrate, concentration: 2.5%, solvent: water and propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: sodium dihydrochalcone, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: same as in Example 34.

Example 37

Nicotine salt solution: nicotine gluconate salt, concentration: 2.5%, solvent: water and propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: trisodium glycyrrhizinate, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: same as in Example 34.

Example 38

Nicotine salt solution: nicotine oxalate, concentration: 2.5%, solvent: water and propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: meglumine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5: 8.5), (add to) total amount: 100 ml.

Atomization device: same as in Example 34.

Example 39

Nicotine salt solution: galactose diacid nicotine salt, concentration: 2.5%, solvent: water and propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml ；

Alkaline solution: sodium saccharin, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: same as in Example 34.

Example 40

Nicotine salt solution: nicotine glucarate, concentration: 2.5%, solvent: water, propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml ；

Alkaline solution: pyridoxine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: same as in Example 34.

Example 41

Nicotine salt solution: nicotine glutamate, concentration: 2.5%, solvent: water, propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: thiamine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5: 8.5), (add to) total amount: 100 ml.

Atomization device: same as in Example 34.

Example 42

Nicotine salt solution: aspartic acid nicotine salt, concentration: 2.5%, solvent: water, propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml ；

Alkaline solution: pyridoxamine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: the same as in Example 34.

Example 43

Nicotine salt solution: nicotine benzoate, concentration: 2.5%, solvent: water and propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: arginine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total: 100ml.

Atomization device: the same as in Example 34.

Example 44

Nicotine salt solution: nicotine salt of ascorbate, concentration: 2.5%, solvent: water, propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: lysine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5: 8.5), (add to) total amount: 100 ml.

Atomization device: the same as in Example 34.

Example 45

Nicotine salt solution: nicotine salt of dehydroascorbate, concentration: 2.5%, solvent: water and propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5:1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: sodium methionine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: same as in Example 34.

Example 46

Nicotine salt solution: nicotine erythorbate, concentration: 2.5%, solvent: water, propylene glycol, polydipropylene glycol (volume ratio 1.5:7.5:1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: sodium glycinate, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: the same as in Example 34.

Example 47 (Comparative Example 34)

Nicotine salt solution: nicotine hydrochloride salt, concentration: 2.5%, solvent: water, propylene glycol, polydipropylene glycol (volume ratio 1.5:7.5:1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: ethanolamine, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: the same as in Example 34.

Example 48 (Comparative Example 35)

Nicotine salt solution: nicotine citrate salt, concentration: 2.5%, solvent: water and propylene glycol, polydipropylene glycol (volume ratio 1.5: 7.5: 1), pH value: 5.0, (add to) total: 100ml;

Alkaline solution: sodium hydrogen phosphate, concentration: 1.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), (add to) total amount: 100ml.

Atomization device: same as in Example 34.

Example 49

Nicotine salt mixture: nicotine isovalerate, content: 1.5%, diluent or aerosol generator: sorbitol, (add to) total: 100g;

Alkaline solution: triethanolamine, concentration: 1.5%, solvent: propylene glycol, (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201390000294.7 or a commercially available electronic smoking set.

Example 50

Nicotine salt mixture: 2-methylbutyrate nicotine salt, content: 3.5%, diluent or aerosol generator: 1,3-dihydroxyacetone, (add to) total amount: 100g;

Alkali mixture: urea, content: 1.5%, diluent or aerosol generating agent: sorbitol, (add to) total amount: 100g.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201390000291.3 or a commercially available electronic smoking set.

Example 51

Nicotine salt mixture: nicotine benzoate, content: 2.5%, diluent or aerosol generator: erythrose, (add to) total: 100g;

Alkali mixture: meglumine, content: 1.0%, diluent or aerosol generator: xylitol, (add to) total amount: 100g.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the invention patent CN201410371441.2 or a commercially available electronic smoking set.

Example 52

Nicotine salt solution: phenylacetic acid nicotine salt, concentration: 0.5%, solvent: water and propylene glycol (volume ratio 1.5:8.5), pH value: 6.4, (add to) total: 100ml;

Alkali mixture: thiamine, content: 2.0%, diluent or aerosol generator: erythritol, (add to) total: 100g.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the invention patent CN200710121524.6 or a commercially available electronic smoking set.

Example 53

Nicotine salt mixture: Nicotine isocaproate salt, content: 2.0%, diluent or aerosol generator: fructose, (add to) total: 100g;

Alkali mixture: Diarno, content: 1.0%, diluent or aerosol generator: menthol, (add to) total amount: 100g.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201621239037.0 or a commercially available electronic smoking set.

Example 54

Nicotine salt mixture: nicotine butyrate salt, content: 4.5%, diluent or aerosol generator: lactic acid, (add to) total amount: 100g;

Alkali mixture: arginine, content: 85%, diluent or aerosol generating agent: menthol, (add to) total: 100g.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201720429415.X or a commercially available electronic smoking set.

Example 55

Nicotine salt mixture: nicotine propionate, content: 2.0%, diluent or aerosol generator: lauric acid, (add to) total: 100g;

Alkaline solution: Tripentanolamine, concentration: 2.5%, solvent: water, propylene glycol, glycerin (volume ratio 1.5:6.5:2), (add to) total amount: 100ml.

Atomization device: Device example 4-1 in the specification (ie the device shown in Figures 1-1 to 6).

Example 56

Nicotine salt mixture: nicotine acetate, content: 2.5%, diluent or aerosol generator: xylose, (add to) total: 100g;

Alkali mixture: ammonium glycinate, content: 75%, diluent or aerosol generator: myristyl alcohol, (add to) total amount: 100g.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201720429415.X or a commercially available electronic smoking set.

Example 57

Nicotine salt solution: nicotine benzoate, concentration: 3.5%, solvent: water, triethylene glycol, propylene carbonate (volume ratio 1.5:6.5:2), pH value: 6.5, (add to) total: 100ml ；

Alkaline solution: meglumine, concentration: 1%, solvent: water and tetraethylene glycol (volume ratio 3:7), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and incommunicable tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and combined for oral inhalation, the larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201621239037.0 or a commercially available electronic smoking set.

Example 58

Nicotine salt solution: carboxyglutamate nicotine salt, concentration: 1.5%, solvent: water and ethyl lactate (volume ratio 2:8), pH value: 6.2, (add to) total: 100ml;

Alkaline solution: lysine, concentration: 2.5%, solvent: water, propylene glycol, glycerin (volume ratio 1.5:7.5:1), (add to) total amount: 100ml.

Atomizing device: Device example 4-2 in the specification (ie the device shown in Figures 21-2).

Example 59

Nicotine salt solution: nicotine salt of glycyrrhizinate, concentration: 0.5%, solvent: water and propylene glycol, triacetin (volume ratio 1.5:6.5:2), pH value: 6.1, (add to) total: 100ml ；

Alkaline solution: tromethamine, concentration: 0.5%, solvent: ethanol and ethyl myristate (volume ratio 0.5:9.5), (add to) total amount: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and unconnected tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and used for oral inhalation after being combined. The larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the invention patent CN200710121524.6 or a commercially available electronic smoking set.

Example 60

Nicotine salt mixture: nicotine salt of glycyrrhizinate, content: 1.0%, diluent or aerosol generator: ethyl vanillin, (add to) total: 100g;

Alkaline solution: diethanolamine, concentration: 0.5%, solvent: ethanol and dimethyl dodecanedioate (volume ratio 0.5:9.5), (add to) total: 100ml.

Atomization device: Two identical independent e-cigarettes are connected by two independent and unconnected tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and used for oral inhalation after being combined. The larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201621239037.0 or a commercially available electronic smoking set.

Example 61

Nicotine salt mixture: 2-methylbutyrate nicotine salt, content: 75%, diluent or aerosol generator: phenylacetic acid, (add to) total: 100g;

Alkali mixture: urea, content: 1.0%, diluent or aerosol generator: arabinose, (add to) total: 100g.

Atomization device: Two identical independent e-cigarettes are connected by two independent and unconnected tubes (such as rubber tubes, silicone tubes) of different sizes at both ends, and used for oral inhalation after being combined. The larger of the above-mentioned tubes One end is connected to the smoke outlet of the smoking set, and the smaller end is used for oral inhalation, and the outer diameter of the smaller end is 3mm-4mm. The electronic smoking set is the smoking set disclosed in the utility model patent CN201390000291.3 or a commercially available electronic smoking set.

Example 62

Nicotine salt solution: nicotine isopropionate, concentration: 1.5%, solvent: 2,2-dimethyl-1,3-dioxolane-4-methanol, (add to) total amount: 100ml;

Alkaline solution: triethanolamine, concentration: 1.5%, solvent: 1,3-propanediol monolactate, (add to) total amount: 100ml.

Atomization device:

Embodiment 62-1: Device example 4-1 in the specification (ie, the device shown in Figures 1-1 to 6).

Embodiment 62-2: Others are the same, only the two “mist or smoke passages or guides 1” in the atomization device in the embodiment are changed to “the other end communicates with a suction (mouth) hole” It is "the other end is connected with one suction (nozzle) hole", that is, two suction (nozzle) holes become one suction (nozzle) hole.

Example 63

Nicotine salt solution: L-gulonic acid nicotine salt, concentration: 1.5%, solvent: tetrahydrofuran polyethylene glycol ether, (add to) total amount: 100ml;

Alkaline solution: chitobiose, concentration: 1.5%, solvent: water and 1,3-dioxolane-4-methanol (volume ratio 0.5:9.5), (add to) total amount: 100ml.

Atomization device:

Embodiment 63-1: Device Example 4-2 in the specification (ie, the device shown in Figures 21-2).

Example 63-2: Other things are the same, only the two "mist or smoke passages or guides 1" in the atomization device in the example are changed to "the other end is communicated with a suction (mouth) hole" It is "the other end is connected with one suction (nozzle) hole", that is, two suction (nozzle) holes become one suction (nozzle) hole.

Example 64

Nicotine salt solution: D-lactate nicotine salt, concentration: 1.5%, solvent: 1,3-dioxan-5-ol, (add to) total amount: 100ml;

Alkaline solution: triisopropanolamine, concentration: 1.5%, solvent: 1,3-propanediol monoethyl ester, (add to) total amount: 100 ml.

Atomization device:

Embodiment 64-1: Device Example 4-3 in the specification (ie, the device shown in Figure 3-1).

Example 64-2: Others are the same, only the two "mist or smoke passages or guides 1" in the atomization device in the embodiment are changed to "the other end communicates with a suction (mouth) hole" It is "the other end is connected with one suction (nozzle) hole", that is, two suction (nozzle) holes become one suction (nozzle) hole.

Example 65

Nicotine salt solution: nicotine salt of glucoheptonate, concentration: 1.5%, solvent: water and 1,3-dioxan-5-ol (volume ratio 1:9), pH value: 5.2, (add to) Total amount: 100ml;

Alkaline solution: Dipentanolamine, concentration: 1.5%, solvent: 1,3-propanediol monopropyl ester, (add to) total amount: 100ml.

Atomization device:

Example 65-1: Device example 4-4 in the specification, the lower and upper shells are set according to device example 4-4 in the specification, according to the power supply assembly, atomization subsystem, and accessories disclosed in the invention patent CN206079032U or CN200910080147.5 Etc., there are two sets of the same but independent and unconnected devices containing the power components, atomization subsystems, accessories and other components disclosed in the above patent (all the same as the patent); or the device example in the specification 4- 1 (ie the device shown in Figures 1-1 to 6).

Example 65-2: Other things are the same, only the two "mist or smoke passages or guides 1" in the atomization device in the embodiment are changed to "the other end communicates with a suction (mouth) hole" It is "the other end is connected with one suction (nozzle) hole", that is, two suction (nozzle) holes become one suction (nozzle) hole.

The preparation method of nicotine salt in the above-mentioned embodiment adopts methods known in the art or directly adopts nicotine salt therein, such as CN1607950A, CN101222915A, CN201480025499.X, CN201580038462.5, CN201180028544.3, CN201680079884.1, CN201180022735.9 , CN03812809.8, etc.;

The preparation method of the above nicotine salt can also adopt the following simple methods:

Take excess nicotine (the acid equivalent ratio is greater than 1.2, in order to save, generally do not exceed 1.5) of nicotine (free state) and acid (pKa value lower than nicotine) aqueous solution and mix, after the reaction is basically completed (the pH value of the solution is determined to be stable Alkaline value) solution spray drying (normal temperature to temperature 120 ℃) or freeze spray drying, remove the water and excessive volatile free nicotine, nicotine salt can be obtained.

Description: 1) The pH regulators of the above embodiments are each (0.1 mol/l) acid or hydrochloric acid or sodium hydroxide solution that forms a salt with nicotine;

2) The above solutions and mixtures are uniformly mixed;

3). The above nicotine salt solution/mixture and alkali solution/mixture are respectively placed in the two isolated and unconnected liquid storage chambers (parts)/or containing chambers (or containing chambers) in the above atomization device, or a combination of the above The objects (I) and (II) are respectively pre-placed in containers such as glass, ceramic, metal, etc., and then placed together with the above-mentioned container in the two isolated and incommunicable liquid storage chambers/or containing chambers (or chambers).

Comparative example 1～33-1, 49～61-1

The reference substance is prepared according to the following method:

Respectively mix the equivalent amount of nicotine salt solution or nicotine salt mixture (such as 10ml or 10g) and its alkali solution or alkali mixture (such as 10ml or 10g) in the corresponding embodiment to obtain the reference substance in the control example. (For example, 10ml of nicotine salt solution (or 10g of nicotine salt mixture) and 10ml of alkali solution (or 10g of alkali mixture) in each corresponding embodiment are uniformly mixed to obtain the reference substance of each corresponding control example), use this The mixed reference substance replaces the nicotine salt solution and alkali solution/or alkali mixture in the corresponding embodiment.

Atomization device: the same as its corresponding embodiment.

Comparative example 1～33-2, 49～61-2

Reference substance:

1). Nicotine salt solution or nicotine salt mixture: it corresponds to the nicotine salt solution or nicotine salt mixture in the embodiment, that is, the same as the corresponding embodiment, unchanged; and

2) Replace the alkali solution/or alkali mixture in the corresponding embodiment with a neutralized alkali solution or a neutralized alkali mixture, and prepare according to the following method:

Neutralized alkali solution: Take the same amount of the corresponding alkali in each corresponding embodiment, add about 85% of the total amount of the corresponding solvent, mix well, and adjust with (0.1mol/l) hydrochloric acid or sodium hydroxide solution When the pH value reaches 6.9～7.1, add the remaining amount of the corresponding solvent to the full amount (ie 100ml); or

Neutralized alkali mixture: Take the hydrochloride salt of the corresponding alkali in each corresponding embodiment (that is, it has been neutralized with hydrochloric acid), and add an appropriate amount of the corresponding diluent or aerosol generating agent in the corresponding embodiment , Make the equivalent content the same as the equivalent content of the alkali in the corresponding embodiment (calculated as the free alkali, the content is the same as the corresponding embodiment), and mix well.

The above-mentioned nicotine salt solution 1) and the neutralized alkali solution/or alkali mixture 2) are not mixed together, and the corresponding nicotine salt solution and alkali solution/or alkali mixture in the corresponding embodiments are replaced respectively.

Atomization device: the same as its corresponding embodiment.

Comparative example 1～33-3, 49～61-3

Reference substance:

1) Alkaline nicotine salt solution: the formula and preparation method are basically the same as the nicotine salt solution in the corresponding embodiment (the same as the corresponding embodiment, both have been 2 months from the production date), and the only difference is that it is formed Adjust the pH value of the original acid of the nicotine salt or the alkali in the alkali solution in the corresponding embodiment to 7.2～9.5 (wherein, comparative example 1～3: pH value to 7.2～7.5; comparative example 4～10: pH value To 7.6～8.0; comparative example 11～20: pH value to 8.1～8.5; comparative example 21～33: pH value to 8.6～8.9; comparative example 49～61: pH value to 9.0～9.5; if it is an alkali mixture, no Processing); and

2) Blank solvent without alkali or acid: the alkali in the alkali solution in the corresponding embodiment is removed, and the others remain unchanged, that is, only the original corresponding blank solvent is used.

The above-mentioned alkaline nicotine salt solution 1) and the blank solvent without alkali or acid 2) are not mixed together, and the corresponding nicotine salt solution and alkali solution/or alkali mixture in the corresponding embodiment are replaced respectively.

Atomization device: the same as its corresponding embodiment.

Comparative example 1～33-4, 49～61-4

Reference substance:

1). Nicotine salt solution or nicotine salt mixture: it corresponds to the nicotine salt solution or nicotine salt mixture in the embodiment, that is, the same as the corresponding embodiment, unchanged; and

2) Blank solvent without alkali or acid: the alkali in the alkali solution in the corresponding embodiment is removed, and the others remain unchanged, that is, only the original corresponding blank solvent is used.

The above-mentioned nicotine salt solution, or nicotine salt mixture 1) and the blank solvent without alkali or acid 2) are not mixed together, respectively, replace the corresponding nicotine salt solution and alkali solution/or alkali mixture in the corresponding embodiment .

Atomization device: the same as its corresponding embodiment.

Application method:

Examples 1-33, 49-65

The two liquid storage chambers/accommodating chambers in the device corresponding to each embodiment are respectively injected with the nicotine salt solution (or nicotine salt mixture) and alkali solution (or alkali mixture) in this embodiment, and the nicotine salt solution ( (Or nicotine salt mixture) containing 2-20mg of nicotine (calculated as free nicotine) (that is, a single dose of nicotine is 2-20mg (calculated as free nicotine)), the alkali solution (or alkali mixture) and the nicotine The volume (or weight) of the salt solution (or nicotine salt mixture) is the same. Then the nicotine salt solution (or nicotine salt mixture) and alkali solution (or alkali mixture) are atomized. The user inhales the aerosol once every 6 seconds, and the two aerosols are inhaled deep into the lungs (meeting) and then exhaled Or spit it out until the above solution (or mixture) is atomized.

Examples 34～48

The two liquid storage chambers/liquid containing chambers in the device corresponding to each embodiment are respectively injected with the nicotine salt solution and the alkali solution in this embodiment, and the volume numbers of the nicotine salt solution and the nicotine salt solution are both 0.50 ml. Then the nicotine salt solution and alkali solution are atomized, and the user inhales the aerosol from the mouth (or/and nasal cavity) every 6 seconds, swallows through the throat to the lungs, and inhales the two aerosols deep into the lungs ( After meeting), exhale from the nasal cavity until the above solution is atomized.

Comparative example 1～33-1, 49～61-1

The two liquid storage chambers/accommodating chambers in each comparative example corresponding to the device in its embodiment (the same as the corresponding embodiment apparatus) are injected with the reference substance in the comparative example, and the two liquid storage chambers/accommodating chambers are filled with the reference substance The volume number (or weight) of is the same and is the same as the volume number (or weight of the mixture) injected into the embodiment. Then the solution (or mixture) is atomized, and the user inhales the aerosol from the oral cavity (or/and nasal cavity) every 6 seconds, and swallows it through the throat to the lungs. The two aerosols are inhaled deep into the lungs (meeting) Then exhale from the nasal cavity until the above solution (or mixture) is atomized. The atomization speed is the same as the corresponding embodiment.

Comparative example 1～33-2, 49～61-2

The two liquid storage chambers/accommodating chambers in the device in each comparative example corresponding to the device in the embodiment (the same as the device in the corresponding embodiment) are respectively injected with the reference 1) in the comparative example, that is, the nicotine salt in the corresponding embodiment Solution (or nicotine salt mixture), and reference 2), that is, the neutralized alkali solution (or neutralized alkali mixture) of the control example, the nicotine salt solution (or nicotine salt mixture) and the neutralized The volume of the neutralized alkali solution (or the weight of the neutralized alkali mixture) is the same and is the same as the volume of the solution (or the weight of the mixture) injected according to the embodiment. Then the nicotine salt solution (or nicotine salt mixture) and the neutralized alkali solution (or neutralized alkali mixture) are atomized, and the user inhales air from the mouth (or/and nasal cavity) every 6 seconds Once the mist is swallowed through the throat to the lungs, the two aerosols are inhaled deep into the lungs (when they meet) and then exhaled from the nasal cavity until the above-mentioned solution (or mixture) is atomized. The atomization speed is the same as the corresponding embodiment.

Comparative example 1～33-3, 49～61-3

The two liquid storage chambers/accommodating chambers in each comparative example corresponding to the device in its embodiment (the same as the corresponding embodiment device) are respectively injected with the reference substance 1): alkaline nicotine salt solution and reference substance 2): Blank solvent without alkali or acid. The volume of the reference substance 1) and reference substance 2) are the same and the same as the volume of the solution injected into the embodiment. Then the reference substance 1) and reference substance 2) are atomized. The user inhales the aerosol from the oral cavity (or/and nasal cavity) every 6 seconds, and then swallows it through the throat to the lungs. The two aerosols are inhaled deep into the lungs. Exhale from the nasal cavity after meeting (meeting) until the above-mentioned solution (or mixture) is atomized. The atomization speed is the same as the corresponding embodiment.

Comparative example 1～33-4, 49～61-4

The two liquid storage chambers/accommodating chambers in the device in each comparative example corresponding to its embodiment (the same as the device in the corresponding embodiment) are respectively injected into the reference 1): nicotine salt solution or nicotine salt Mixture and reference substance 2): a blank solvent that does not contain alkali or acid. The volume of the reference substance 1) and reference substance 2) solutions are the same and the same as the volume of the solution injected into the embodiment. Then the reference substance 1) and reference substance 2) are atomized. The user inhales the aerosol from the oral cavity (or/and nasal cavity) every 6 seconds, and swallows it through the throat to the lungs. The two aerosols are inhaled deep into the lungs. Exhale from the nasal cavity after meeting (meeting) until the above-mentioned solution (or mixture) is atomized. The atomization speed is the same as the corresponding embodiment.

Test Example 1 Nicotine Analysis Test

For the nicotine intake method, please refer to the administration method of each embodiment and control example described above. The analysis of the effect of nicotine can be done according to standard methods known in the art, such as using biological analysis for the determination of nicotine in the recipient’s plasma: the user inhales the aerosol, and after the completion of the atomization process, at 10min, 20min, 30min , 1hr, 1.5hr, 2hr, 3hr, 4hr, 6hr, 8hr, 12hr to measure the user's nicotine (as free nicotine) plasma concentration, and calculate AUC _0→∞ (the area enclosed by the plasma concentration curve versus time , Reflecting the bioavailability/degree of nicotine).

The results are shown in Table 4. The results show that the bioavailability/degree and other in vivo behaviors of the examples are better than those of the control examples.

Test Example 2 Sensory Quality Inspection of Electronic Cigarette

Refer to the sensory quality detection method of e-cigarette liquid disclosed in patent CN201410788599.X. The specific steps are as follows:

1) Set 4 sensory quality testing indicators, the selected 4 sensory quality testing indicators are: throat (or choking) sensation, irritation, satisfaction, comfort, the throat sensation (or choking) refers to: The free nicotine in the smoke generated by inhaling the e-cigarette liquid through atomization chokes the throat to cause coughing, and makes the throat feel oppressive, such as "choking the smoke" uncomfortable feeling; the irritation refers to: inhalation The smoke produced by the atomization of e-cigarette liquid has various uncomfortable feelings on sensory organs including the mouth, throat, and nasal cavity, such as cold, heat, pain, itching, sour, pungent, spicy, bitter, salty, numb, astringent, etc. The satisfaction refers to the comprehensive feeling of the intensity and concentration of the smoke produced by the atomization of the e-cigarette liquid on the sensory organs; the comfort refers to the smoke produced by the atomization of the e-cigarette liquid The effect on oral comfort after inhalation and exhalation;

2) Adopt the overall circulation evaluation method, and smoke the e-cigarette liquid through the e-cigarette smokers (see the application method of each embodiment and control example described above for the method). The overall circulation evaluation method refers to: evaluation The smoke produced by the atomization of the e-cigarette liquid during smoking is inhaled through the mouth, swallowed from the throat to the lungs, exhaled from the nasal cavity, and the whole process of feeling and capturing the characteristics of the smoke. The panelists are set to 51;

3) The judges use the scoring method to comprehensively score the sensory quality of the e-cigarette liquid, reflecting the degree of influence of various sensory quality test indicators on the quality of the e-cigarette. The scoring method refers to: 4 sensory quality inspection indicators are scored on a scale of 0, 5, 10, 15, 20, and 25 (as shown in Table 3), and the 4 sensory quality inspection indicators can be evaluated individually , Can also be evaluated by the total score (up to 100 points). The higher the sensory quality score, the better the quality of the e-cigarette liquid.

Table 3 Meaning table of score values of sensory quality test indicators

The minimum scoring unit of the scoring value is 0.5.

4) Counting the sensory quality test results of the reviewers. The method for statistically calculating the sensory quality test results of the reviewers includes the following steps: scoring all sensory quality test indicators of all reviewers, Remove a minimum score and a high score respectively, and calculate the average value of the effective score for each sensory quality test index.

The results are shown in Table 5. The results show that the sensory quality of the example is better than that of the control example in terms of hitting/choking sensation or satisfaction and comfort.

Test Example 3 Nicotine Stability Test I

The nicotine salt solution samples in the example and the control example (reference) were encapsulated in a colorless and transparent 5ml ampoule (sealed), and placed at a temperature of 35～40℃, a relative humidity of 60～75% and a medium light intensity ( In the same environment of about 50～150LUX), take it out at the same time after 1～2 months, and measure the total nicotine content (bound and free state) and related substances (oxidative degradation products of nicotine) in the nicotine salt solution sample (The result is expressed by the relative label amount), calculate the relative 0 month (that is, before putting), the total nicotine amount decrease value A (%) and related substance increase value B (%).

The results are shown in Table 6. The results show that the stability of nicotine in the examples is better than that in the control examples.

Nicotine stability test Ⅱ

Fill the nicotine salt solution samples in the example and the control example (reference substance) into a 50ml open bottle (unsealed) at the same time at a temperature of 20～25℃, a relative humidity of 60～75% and no light. In the environment, take it out at the same time after 1 to 2 months, determine the total nicotine content (bound and free state) in the nicotine salt solution sample (the result is expressed by the relative labeled amount), and calculate the relative 0 month (that is, before placing), The total nicotine content decreased value A'(%).

The results are shown in Table 7. The results show that the nicotine stability of the examples is better than that of the control examples.

Found in the test:

The performance of Example (X) is relatively smooth and supple when used, with better throat and/or oral sex, better satisfaction and comfort; while the corresponding control examples X-1 and X-3 perform more vigorously. Throat choking sensation is greater, or irritation is greater, throat and/or oral sex is poor, users (especially those who use tobacco products for the first time or infrequently) develop a certain degree of "resistance", involuntarily Refusal to inhale smoke into the lungs or mouth greatly affects satisfaction and comfort.

The device used in the embodiment has two suction (nozzle) holes or vent holes compared with one suction (nozzle) hole or vent hole test, which shows the following advantages:

1). It can better reduce the choking sensation of e-cigarettes (produced by free nicotine), and greatly improve the comfort: because the smoke of nicotine salt meets the alkaline smoke to produce free nicotine, the free nicotine is more smoke Alkali salt choking feeling is much greater, and the space in the mouth and throat is many, many times larger than the small vent on the cigarette holder. The smoke and alkaline smoke of nicotine salt pass through two outlets in the mouth and throat. The internal meeting produces free nicotine, and the amount of free nicotine produced when they meet together through a small vent on the cigarette holder is much less (because in a larger space, the density of nicotine salt and alkali is less and more dilute. There are fewer chances for the reaction to generate free nicotine), and a considerable proportion of free nicotine is produced in the lungs, rather than in the mouth and throat, so the choking sensation is much less and more The earth improves the comfort level, which is more improved than the amount of free nicotine that has been produced before the entrance (such as adjusting the pH value of the nicotine salt solution to alkaline);

2). The user can really experience two different flavors of smoke: Since the vents are straight through the mouth, the two vents can each output one flavor of smoke into the mouth, allowing users to experience two different flavors of smoke at the same time However, in the previous technical solution, because there is only one vent, the two flavors of smoke are mixed in the smoking set in advance. In fact, only one flavor of smoke can be output in the mouth forever, and users can only experience one flavor of smoke.

Table 4-1 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 1 5.2 11.3 Example 2 22.6 39.7 Comparative Example 1-1 3.1 7.4 Comparative Example 2-1 13.5 24.4 Comparative example 1-2 1.4 2.7 Comparative example 2-2 3.8 8.3 Comparative example 1-3 1.8 3.6 Comparative example 2-3 4.2 9.9

Table 4-2 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 3 13.5 28.8 Example 4 15.8 34.9 Comparative Example 3-1 7.9 17.9 Comparative Example 4-1 10.2 22.8 Comparative example 3-2 4.1 9.7 Comparative example 4-2 7.7 16.7 Comparative example 3-3 4.5 11.3 Comparative example 4-3 8.9 19.7

Table 4-3 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 5 17.7 38.6 Example 6 20.6 51.8 Comparative Example 5-1 10.8 23.5 Comparative Example 6-1 12.7 28.9 Comparative example 5-2 5.2 9.8 Comparative Example 6-2 4.7 10.4 Comparative example 5-3 7.7 13.8 Comparative Example 6-3 7.9 15.4

Table 4-4 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 7 14.7 35.5 Example 8 20.3 54.6 Comparative Example 7-1 8.9 20.3 Comparative Example 8-1 13.7 30.3 Comparative Example 7-2 3.4 8.1 Comparative Example 8-2 8.8 20.4 Comparative Example 7-3 5.1 12.6 Comparative Example 8-3 10.4 25.9

Table 4-5 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 9 22.7 51.3 Example 10 8.8 21.7 Comparative Example 9-1 14.6 33.8 Comparative Example 10-1 5.5 12.9 Comparative Example 9-2 5.1 13.8 Comparative Example 10-2 2.4 6.2 Comparative Example 9-3 7.8 21.7 Comparative Example 10-3 3.8 9.7

Table 4-6 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 11 21.6 50.4 Example 12 14.6 35.6 Comparative Example 11-1 13.8 30.7 Comparative Example 12-1 8.5 22.4 Comparative example 11-2 4.8 11.6 Comparative Example 12-2 6.3 15.8 Comparative example 11-3 8.2 21.8 Comparative Example 12-3 7.6 19.8

Table 4-7 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 13 23.8 55.8 Example 14 9.3 25.8 Comparative Example 13-1 15.4 35.9 Comparative Example 14-1 6.2 15.7 Comparative Example 13-2 5.8 14.6 Comparative Example 14-2 2.7 6.5 Comparative Example 13-3 8.9 23.8 Comparative Example 14-3 4.5 11.4

Table 4-8 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 15 21.6 53.8 Example 16 32.7 76.8 Comparative Example 15-1 14.5 36.3 Comparative Example 16-1 21.6 48.7 Comparative Example 15-2 5.8 13.8 Comparative Example 16-2 7.6 21.4 Comparative Example 15-3 9.3 24.6 Comparative Example 16-3 12.8 38.6

Table 4-9 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 17 23.6 57.4 Example 18 9.5 27.5 Comparative Example 17-1 16.5 37.2 Comparative Example 18-1 6.1 15.8 Comparative Example 17-2 5.8 14.7 Comparative Example 18-2 4.3 10.2

Comparative Example 17-3 9.8 24.6 Comparative Example 18-3 5.3 12.8

Table 4-10 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 19 26.6 61.5 Example 20 33.5 78.8 Comparative Example 19-1 17.3 42.9 Comparative Example 20-1 19.8 46.8 Comparative Example 19-2 6.8 17.8 Comparative Example 20-2 8.8 21.9 Comparative Example 19-3 10.2 33.8 Comparative Example 20-3 13.6 37.7

Table 4-11 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 21 39.6 90.7 Example 22 34.2 76.4 Comparative Example 21-1 23.4 57.1 Comparative Example 22-1 18.7 51.2 Comparative example 21-2 6.5 17.2 Comparative Example 22-2 5.8 15.2 Comparative Example 21-3 22.7 60.9 Comparative Example 22-3 22.8 56.6

Table 4-12 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 23 25.6 62.7 Example 24 37.7 85.4 Comparative Example 23-1 18.4 43.9 Comparative example 24-1 23.5 53.6 Comparative Example 23-2 8.9 21.5 Comparative Example 24-2 9.4 27.3 Comparative Example 23-3 17.3 45.8 Comparative example 24-3 22.9 50.8

Table 4-13 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 25 18.7 46.1 Example 26 37.3 87.6 Comparative Example 25-1 11.6 25.3 Comparative Example 26-1 20.4 48.9 Comparative Example 25-2 7.2 17.8 Comparative Example 26-2 7.6 19.4 Comparative Example 25-3 13.1 34.7 Comparative Example 26-3 18.1 43.3

Table 4-14 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 27 17.9 44.9 Example 28 15.6 38.9 Comparative Example 27-1 10.5 25.7 Comparative Example 28-1 10.2 24.5 Comparative Example 27-2 6.4 15.3 Comparative Example 28-2 4.7 11.5 Comparative Example 27-3 12.5 30.6 Comparative Example 28-3 12.0 28.6

Table 4-15 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 29 26.8 67.3 Example 30 17.3 43.6 Comparative Example 29-1 15.1 38.3 Comparative Example 30-1 10.6 26.2 Comparative Example 29-2 4.4 12.5 Comparative Example 30-2 3.8 9.2 Comparative Example 29-3 19.4 46.8 Comparative Example 30-3 11.2 30.3

Table 4-16 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 31 15.7 41.3 Example 32 38.3 89.5 Comparative Example 31-1 10.2 25.8 Comparative Example 32-1 21.6 57.3 Comparative example 31-2 4.1 10.6 Comparative Example 32-2 7.8 20.4 Comparative Example 31-3 9.1 22.5 Comparative Example 32-3 19.6 51.5

Table 4-17 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 33 17.8 50.4 Example 49 18.6 49.4 Comparative Example 33-1 11.4 31.5 Comparative Example 49-1 12.3 32.8 Comparative Example 33-2 6.7 20.8 Comparative Example 49-2 6.9 18.7 Comparative Example 33-3 9.5 25.1 To To To

Table 4-18 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 50 26.8 83.7 Example 51 20.4 74.6 Comparative example 50-1 17.8 48.8 Comparative Example 51-1 13.1 42.7 Comparative Example 50-2 9.6 30.5 Comparative Example 51-2 7.2 24.8

Table 4-19 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 52 10.8 30.7 Example 53 21.8 62.7 Comparative Example 52-1 6.2 19.4 Comparative Example 53-1 12.1 38.2 Comparative Example 52-2 3.6 12.2 Comparative Example 53-2 5.6 19.4

Table 4-20 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 54 42.7 134.6 Example 55 23.8 66.8

Comparative Example 54-1 27.2 83.7 Comparative Example 55-1 12.3 41.1 Comparative Example 54-2 14.8 46.2 Comparative Example 55-2 7.7 25.2

Table 4-21 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 56 28.2 86.7 Example 57 20.6 72.4 Comparative Example 56-1 16.3 53.2 Comparative Example 57-1 13.7 46.3 Comparative Example 56-2 8.4 31.2 Comparative Example 57-2 7.1 25.4 To To To Comparative Example 57-3 15.1 51.7

Table 4-22 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 58 18.3 64.7 Example 59 12.8 44.8 Comparative Example 58-1 11.5 38.6 Comparative Example 59-1 7.2 24.7 Comparative Example 58-2 5.9 19.6 Comparative Example 59-2 4.5 17.6 Comparative Example 58-3 10.4 31.7 Comparative Example 59-3 6.8 21.7

Table 4-23 Nicotine analysis: 10min blood concentration C _10min (ng/ml) and AUC _0→∞ (ng·hr/ml) test results

To C _10min AUC _0→∞ To C _10min AUC _0→∞ Example 60 15.7 53.8 Example 61 20.5 71.6 Comparative Example 60-1 8.6 29.6 Comparative Example 61-1 13.1 43.2 Comparative Example 60-2 4.9 18.7 Comparative Example 61-2 6.8 23.5 Comparative Example 60-3 8.0 26.3 To To To

Note: The unit of C _{10min in the} above tables is ng/ml; the unit of AUC _0→∞ is ng·hr/ml.

Table 5-1 Sensory quality test results of electronic cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 1 20.3 15.9 16.3 17.6 Comparative Example 1-1 5.7 16.0 10.2 7.4 Comparative example 1-3 16.8 8.7 4.5 6.2

Table 5-2 Sensory quality test results of electronic cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 2 18.5 15.9 21.4 20.6 Comparative Example 2-1 5.8 15.1 15.4 8.2 Comparative example 2-3 16.3 7.4 5.3 7.3

Table 5-3 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 3 21.6 17.4 18.4 20.2 Comparative Example 3-1 6.9 16.7 12.3 9.2 Comparative example 3-3 17.2 6.3 7.7 12.5 Comparative example 3-4 20.8 4.1 2.2 13.7

Table 5-4 Sensory quality test results of electronic cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 4 20.8 17.1 19.3 19.7 Comparative Example 4-1 7.7 16.8 12.2 8.9 Comparative example 4-3 15.6 9.7 10.3 10.2

Table 5-5 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 5 21.3 20.1 22.4 22.7 Comparative Example 5-1 7.8 19.5 15.7 11.2 Comparative example 5-3 14.2 8.3 10.5 12.3

Table 5-6 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 6 20.1 18.8 23.2 19.4 Comparative Example 6-1 3.6 17.3 16.2 12.8 Comparative Example 6-3 15.8 9.6 10.5 10.3 Comparative Example 6-4 18.6 5.8 3.7 9.7

Table 5-7 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 7 21.7 20.3 22.8 21.4 Comparative Example 7-1 6.3 18.7 15.3 13.8 Comparative Example 7-3 15.2 8.8 10.6 11.3

Table 5-8 Sensory quality test results of electronic cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 8 19.6 21.6 22.4 20.7 Comparative Example 8-1 5.5 17.6 15.2 13.8

Comparative Example 8-3 14.7 9.5 11.4 10.6 Comparative Example 8-4 16.8 6.3 7.8 9.8

Table 5-9 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 9 19.5 21.7 22.6 21.8 Comparative Example 9-1 4.6 16.8 16.7 12.4 Comparative Example 9-3 15.4 9.2 10.8 11.3

Table 5-10 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 10 22.8 21.8 18.7 23.6 Comparative Example 10-1 6.8 16.6 12.6 14.5 Comparative Example 10-3 15.6 9.6 9.4 11.5

Table 5-11 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 11 18.9 20.5 22.7 20.8 Comparative Example 11-1 5.8 6.8 16.5 14.8 Comparative example 11-3 12.2 10.8 12.8 12.3 Comparative example 11-4 17.8 4.2 5.8 8.5

Table 5-12 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 12 19.3 18.5 21.6 20.5 Comparative Example 12-1 5.8 14.5 15.7 15.3 Comparative Example 12-3 13.2 10.3 11.2 12.8

Table 5-13 Sensory quality test results of electronic cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 13 18.6 21.6 21.8 20.6 Comparative Example 13-1 4.5 15.8 16.3 14.7 Comparative Example 13-3 12.4 11.7 12.8 13.7 Comparative example 13-4 16.8 4.8 6.5 9.3

Table 5-14 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 14 21.4 18.9 18.4 20.7 Comparative Example 14-1 7.8 13.6 12.6 13.6 Comparative Example 14-3 11.8 9.2 9.7 11.2

Table 5-15 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 15 19.4 15.6 20.5 16.7 Comparative Example 15-1 6.2 12.7 15.3 10.3 Comparative Example 15-3 12.2 10.6 10.5 10.5 Comparative Example 15-4 17.2 7.2 7.1 8.3

Table 5-16 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 16 18.8 20.7 23.5 19.9 Comparative Example 16-1 4.2 19.9 16.8 12.5 Comparative Example 16-3 12.6 10.3 11.7 11.8

Table 5-17 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 17 20.5 22.5 21.7 20.5 Comparative Example 17-1 5.7 20.4 15.8 14.6 Comparative Example 17-3 13.2 11.2 10.6 12.7

Table 5-18 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 18 21.6 23.9 17.8 22.8 Comparative Example 18-1 7.9 19.9 12.3 15.4 Comparative Example 18-3 11.8 9.6 9.7 12.6 Comparative Example 18-4 14.8 6.8 7.3 9.6

Table 5-19 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 19 18.7 20.8 23.5 21.7 Comparative Example 19-1 3.6 16.4 16.5 15.5 Comparative Example 19-3 12.8 10.6 11.4 13.8

Table 5-20 Sensory quality test results of electronic cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 20 17.5 19.8 23.8 18.9 Comparative Example 20-1 2.8 14.6 16.2 12.6 Comparative Example 20-3 12.1 10.2 12.7 10.5

Table 5-21 Sensory quality test results of electronic cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 21 18.6 17.5 23.6 18.9 Comparative Example 21-1 3.7 13.8 15.7 11.7 Comparative Example 21-3 9.4 10.5 14.8 10.7 Comparative Example 21-4 17.8 5.8 6.2 8.9

Table 5-22 Sensory quality test results of electronic cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 22 17.4 20.5 23.2 20.6 Comparative Example 22-1 2.2 16.5 16.4 13.8 Comparative Example 22-3 4.9 14.7 16.8 11.3

Table 5-23 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 23 18.8 21.6 20.5 21.9 Comparative Example 23-1 4.3 18.5 15.3 14.9 Comparative Example 23-3 6.7 15.8 14.9 13.8

Table 5-24 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 24 17.8 20.6 22.7 20.3 Comparative example 24-1 3.2 16.2 15.6 14.7 Comparative example 24-3 8.6 12.9 12.7 12.2

Table 5-25 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 25 18.5 18.5 20.3 19.5 Comparative Example 25-1 7.2 15.2 14.7 12.3 Comparative Example 25-3 8.8 12.8 12.6 10.7

Table 5-26 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 26 18.2 20.3 23.3 20.6 Comparative Example 26-1 3.2 15.3 15.9 13.2 Comparative Example 26-3 8.5 12.4 13.1 12.4 Comparative Example 26-4 17.5 6.7 7.5 8.8

Table 5-27 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 27 21.4 15.4 20.4 17.4 Comparative Example 27-1 5.8 13.6 14.1 11.6 Comparative Example 27-3 8.9 12.1 12.7 10.2

Table 5-28 Sensory quality test results of electronic cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 28 21.6 18.7 20.8 18.7 Comparative Example 28-1 6.7 16.4 14.8 11.6 Comparative Example 28-3 8.4 12.6 12.8 10.7

Table 5-29 Sensory quality test results of electronic cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 29 19.6 21.8 21.6 20.6 Comparative Example 29-1 4.8 15.7 16.4 14.3 Comparative Example 29-3 7.2 11.8 12.5 11.7 Comparative Example 29-4 18.5 5.3 6.4 9.3

Table 5-30 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 30 21.3 16.5 18.6 17.7 Comparative Example 30-1 6.5 14.4 12.8 11.7 Comparative Example 30-3 8.5 11.8 11.7 10.3

Table 5-31 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 31 21.5 16.8 19.3 16.6 Comparative Example 31-1 7.8 14.6 13.7 10.4

Table 5-32 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 32 20.8 14.5 21.7 13.4 Comparative Example 32-1 7.2 13.1 15.4 8.3 Comparative Example 32-3 8.6 12.4 12.9 10.3 Comparative Example 32-4 14.8 8.7 8.3 8.5

Table 5-33 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 33 20.4 16.1 19.6 15.6 Comparative Example 33-1 5.8 14.6 14.7 9.5

Table 5-34 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 34 - 22.3 - 24.5 Example 35 - 23.3 - 23.5 Example 36 - 23.5 - 24.3 Example 37 - 23.3 - 24.5 Example 38 - 22.1 - 22.4 Example 39 - 22.8 - 22.2 Example 40 - 24.2 - 22.5 Example 41 - 23.5 - 22.3 Example 42 - 23.5 - 22.5 Example 43 - 22.0 - 22.0 Example 44 - 24.5 - 22.5 Example 45 - 23.0 - 22.0 Example 46 - 23.5 - 24.5 Example 47/Comparative Example 34 - 14.5 - 13.5 Example 48/Comparative Example 35 - 13.5 - 14.0

Table 5-35 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 49 21.2 15.3 21.3 16.7 Comparative Example 49-1 5.4 14.3 16.3 6.8

Table 5-36 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 50 20.8 16.3 22.3 16.4 Comparative example 50-1 12.7 14.8 16.3 9.3

Table 5-37 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 51 20.4 19.2 21.2 20.6 Comparative Example 51-1 12.3 17.7 14.8 9.9

Table 5-38 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 52 21.2 20.8 19.6 19.3 Comparative Example 52-1 7.2 18.7 14.7 7.5

Table 5-39 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 53 20.8 16.7 20.5 19.6 Comparative Example 53-1 11.8 14.9 13.4 12.5

Table 5-40 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 54 20.4 16.2 19.6 18.6 Comparative Example 54-1 9.8 14.8 12.2 12.5

Table 5-41 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 55 20.7 15.4 19.8 17.9 Comparative Example 55-1 5.5 14.8 11.8 10.3

Table 5-42 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 56 20.8 15.1 20.7 16.4 Comparative Example 56-1 9.3 14.3 12.2 9.5

Table 5-43 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 57 21.4 18.7 20.8 19.7 Comparative Example 57-1 5.2 17.6 12.7 11.8

Comparative Example 57-3 5.6 16.8 12.5 11.3

Table 5-44 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 58 20.8 19.9 18.6 18.6 Comparative Example 58-1 6.8 17.9 10.2 10.5 Comparative Example 58-3 4.8 18.2 10.8 9.2

Table 5-45 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 59 21.5 18.3 16.8 15.9 Comparative Example 59-1 7.8 17.2 8.8 7.6 Comparative Example 59-3 5.3 17.4 11.7 9.5

Table 5-46 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 60 20.8 16.3 18.2 16.4 Comparative Example 60-1 7.9 14.8 11.2 11.3

Table 5-47 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 61 20.5 17.1 19.9 18.6 Comparative Example 61-1 10.8 15.8 12.7 12.3

Table 5-48 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 62-1 23.5 18.3 21.6 22.8 Example 62-2 17.7 17.7 16.7 17.3

Table 5-49 Sensory Quality Test Results of Electronic Cigarettes

To Throat sensation Irritating Satisfaction Comfort Example 63-1 22.5 17.3 21.5 21.6 Example 63-2 17.9 17.8 16.6 16.1

Table 5-50 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 64-1 23.8 17.6 21.2 23.2 Example 64-2 18.4 18.2 17.7 18.3

Table 5-51 Sensory Quality Test Results of Electronic Cigarettes

To Slap/choking Irritating Satisfaction Comfort Example 65-1 22.6 18.4 22.4 21.8 Example 65-2 16.6 17.9 17.2 16.7

Table 6-1 Test Results of Nicotine Stability Test I

To A(%) B(%) To A(%) B(%) Example 1 1.27 1.33 Example 2 0.96 1.13 Comparative Example 1-1 15.7 17.3 Comparative Example 2-1 16.9 18.1 Comparative example 1-3 3.24 3.56 Comparative example 2-3 2.63 3.12

Table 6-2 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 3 1.12 1.25 Example 4 1.18 1.31 Comparative Example 3-1 18.5 19.7 Comparative Example 4-1 13.6 15.4 Comparative example 3-3 3.86 4.26 Comparative example 4-3 5.36 7.83

Table 6-3 Results of Nicotine Stability Test I

To A(%) B(%) To A(%) B(%) Example 5 1.27 1.38 Example 6 1.56 1.75 Comparative Example 5-1 7.36 8.67 Comparative Example 6-1 12.7 14.1 Comparative example 5-3 6.82 7.74 Comparative Example 6-3 5.94 7.88

Table 6-4 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 7 1.48 1.65 Example 8 2.21 3.12 Comparative Example 7-1 12.6 14.3 Comparative Example 8-1 13.7 14.9 Comparative Example 7-3 6.63 7.89 Comparative Example 8-3 8.85 9.72

Table 6-5 Test results of nicotine stability test I

To A(%) B(%) To A(%) B(%) Example 9 1.62 1.96 Example 10 1.47 1.86 Comparative Example 9-1 12.2 13.5 Comparative Example 10-1 13.8 15.1 Comparative Example 9-2 7.92 9.27 Comparative Example 10-3 6.84 7.88

Table 6-6 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%)

Example 11 1.03 1.31 Example 12 2.57 3.13 Comparative Example 11-1 10.4 11.3 Comparative Example 12-1 11.6 12.5 Comparative example 11-3 8.75 9.74 Comparative Example 12-3 9.36 10.2

Table 6-7 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 13 1.16 1.48 Example 14 0.92 1.18 Comparative Example 13-1 18.4 19.7 Comparative Example 14-1 19.6 21.3 Comparative Example 13-3 9.54 11.2 Comparative Example 14-3 10.5 11.6

Table 6-8 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 15 1.36 1.65 Example 16 1.42 1.76 Comparative Example 15-1 16.7 17.5 Comparative Example 16-1 10.3 10.5 Comparative Example 15-3 8.65 9.65 Comparative Example 16-3 12.5 13.8

Table 6-9 Results of Nicotine Stability Test I

To A(%) B(%) To A(%) B(%) Example 17 1.32 1.57 Example 18 2.73 3.21 Comparative Example 17-1 9.73 10.8 Comparative Example 18-1 12.7 15.9 Comparative Example 17-3 10.7 11.6 Comparative Example 18-3 8.76 9.63

Table 6-10 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 19 1.42 1.78 Example 20 1.53 1.83 Comparative Example 19-1 9.36 10.5 Comparative Example 20-1 8.94 9.82 Comparative Example 19-2 13.5 15.1 Comparative Example 20-3 11.6 13.1

Table 6-11 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 21 1.21 1.44 Example 22 1.82 2.13 Comparative Example 21-1 10.5 11.2 Comparative Example 22-1 11.5 13.3 Comparative Example 21-3 15.2 16.1 Comparative Example 22-3 15.7 17.2

Table 6-12 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 23 2.73 3.24 Example 24 2.47 3.02 Comparative Example 23-1 10.2 11.4 Comparative example 24-1 9.87 10.6 Comparative Example 23-3 14.6 15.4 Comparative example 24-3 15.7 16.7

Table 6-13 Test results of nicotine stability test I

To A(%) B(%) To A(%) B(%) Example 25 2.58 3.35 Example 26 1.88 2.35 Comparative Example 25-1 8.63 9.75 Comparative Example 26-1 14.5 15.8 Comparative Example 25-3 14.5 15.2 Comparative Example 26-3 15.6 17.2

Table 6-14 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 27 2.63 3.32 Example 28 1.74 2.05 Comparative Example 27-1 12.5 14.2 Comparative Example 28-1 11.4 13.2 Comparative Example 27-3 15.6 17.3 Comparative Example 28-3 15.8 16.9

Table 6-15 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 29 1.32 1.53 Example 30 0.92 1.22 Comparative Example 29-1 8.94 9.86 Comparative Example 30-1 8.65 9.53 Comparative Example 29-3 14.3 15.6 Comparative Example 30-3 14.8 16.2

Table 6-16 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 32 1.58 2.13 Example 57 2.89 3.34 Comparative Example 32-1 13.5 15.1 Comparative Example 57-1 10.2 11.9 Comparative Example 32-3 15.6 16.8 Comparative Example 57-3 18.6 20.1

Table 6-17 Nicotine stability test I test results

To A(%) B(%) To A(%) B(%) Example 58 2.47 3.12 Example 59 2.76 3.42 Comparative Example 58-1 17.4 19.2 Comparative Example 59-1 15.4 16.8 Comparative Example 58-3 16.5 18.2 Comparative Example 59-3 16.2 18.1

Note: A represents the decrease value of the total nicotine content relative to 0 month (%), and B represents the relative substance increase value (%) relative to 0 month.

Table 7-1 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 1 0.62 Example 2 0.25 Example 3 0.73

Comparative Example 1-1 15.7 Comparative Example 2-1 13.9 Comparative Example 3-1 16.3 Comparative example 1-3 3.64 Comparative example 2-3 4.23 Comparative example 3-3 4.82

Table 7-2 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 4 0.84 Example 5 0.52 Example 6 0.43 Comparative Example 4-1 16.7 Comparative Example 5-1 9.65 Comparative Example 6-1 8.93 Comparative example 4-3 8.94 Comparative example 5-3 13.7 Comparative Example 6-3 10.2

Table 7-3 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 7 0.62 Example 8 0.97 Example 9 0.63 Comparative Example 7-1 9.52 Comparative Example 8-1 10.8 Comparative Example 9-1 11.3 Comparative Example 7-3 10.7 Comparative Example 8-3 12.9 Comparative Example 9-3 12.5

Table 7-4 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 10 0.51 Example 11 0.43 Example 12 0.97 Comparative Example 10-1 10.5 Comparative Example 11-1 15.7 Comparative Example 12-1 13.3 Comparative Example 10-3 9.6 Comparative example 11-3 14.8 Comparative Example 12-3 15.2

Table 7-5 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 13 0.57 Example 14 0.48 Example 15 0.52 Comparative Example 13-1 18.5 Comparative Example 14-1 17.9 Comparative Example 15-1 19.2 Comparative Example 13-3 15.2 Comparative Example 15-3 16.2 Comparative Example 15-3 16.8

Table 7-6 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 16 0.56 Example 17 0.55 Example 18 0.96 Comparative Example 16-1 16.8 Comparative Example 17-1 15.9 Comparative Example 18-1 13.8 Comparative Example 16-3 17.5 Comparative Example 17-3 16.6 Comparative Example 18-3 14.2

Table 7-7 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 19 0.48 Example 20 0.51 Example 21 0.41 Comparative Example 19-1 16.4 Comparative Example 20-1 17.3 Comparative Example 21-1 16.8 Comparative Example 19-3 20.3 Comparative Example 20-3 21.6 Comparative Example 21-3 24.6

Table 7-8 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 22 0.58 Example 23 0.92 Example 24 0.87 Comparative Example 22-1 16.1 Comparative Example 23-1 17.3 Comparative example 24-1 18.3 Comparative Example 22-3 23.2 Comparative Example 23-3 23.8 Comparative example 24-3 24.5

Table 7-9 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 25 0.96 Example 26 0.93 Example 27 0.98 Comparative Example 25-1 14.9 Comparative Example 26-1 18.3 Comparative Example 27-1 14.5 Comparative Example 25-3 24.7 Comparative Example 26-3 22.8 Comparative Example 27-3 25.2

Table 7-10 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 28 0.85 Example 29 0.78 Example 30 0.86 Comparative Example 28-1 15.2 Comparative Example 29-1 16.9 Comparative Example 30-1 14.2 Comparative Example 28-3 24.2 Comparative Example 29-3 23.7 Comparative Example 30-3 24.2

Table 7-11 Results of Nicotine Stability Test II

To A'(%) To A'(%) To A'(%) Example 32 0.56 Example 57 0.92 Example 58 0.89 Comparative Example 32-1 16.8 Comparative Example 57-1 17.2 Comparative Example 58-1 21.3 Comparative Example 32-3 24.8 Comparative Example 57-3 32.8 Comparative Example 58-3 35.3

Table 7-12 Results of Nicotine Stability Test II

To A'(%) To To To To Example 59 093 To To To To Comparative Example 59-1 22.4 To To To To Comparative Example 59-3 28.2 To To To To

Note: A'represents the decrease value (%) of the total nicotine content relative to 0 months.

Claims (57)

An electronic cigarette (energetic, good physical satisfaction, low or no choking sensation, low or no irritation, good throat passage, high nicotine bioavailability (bioavailability), good consumer experience) (Or aerosol generating system/material), characterized in that the electronic cigarette (or aerosol generating system/material) comprises a pharmaceutically acceptable nicotine salt and a pharmaceutically acceptable aerosol or aerosol generating agent The composition (I) and the composition containing a pharmaceutically acceptable alkali stronger than the nicotine (its pKa value is greater than the pKa value of the nicotine) and a pharmaceutically acceptable aerosol or aerosol generating agent (II), (the above compositions (I) and (II) are separated from each other and not blended together), the above compositions (I) and (II) (both are aerosolized or vaporized or aerosolized or aerosolized) Later) are inhaled (in the body (especially in the lungs (alveoli))) in an aerosolized or vaporized state, aerosol or aerosol (aerosol), (in the use (/consumer) In the body (especially in the lungs (alveoli)) meet (produce free nicotine)). The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the composition (I) or (II) is (at room temperature and 25°C) a solid, semi-solid or liquid mixture, or a solution. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the composition (I) or (II) is in a solid state (at room temperature and 25°C), and its dosage form is powder, granule, tablet Agents (including lumps and shaped tablets), capsules. The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the electronic cigarette (or aerosol generating system/material) contains a combination of tobacco leaf materials containing pharmaceutically acceptable nicotine salts Things. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the nicotine salt is a pharmaceutically acceptable inorganic acid salt or an organic acid salt, and the pKa value of the acid is lower than the pKa value of nicotine . The electronic cigarette (or aerosol generating system/material) according to claim 5, characterized in that the pKa value of the acid is lower than the pKa value of nicotine by more than one. The electronic cigarette (or aerosol generating system/material) according to claim 5, characterized in that the pKa value of the acid is lower than the pKa value of nicotine by more than two. The electronic cigarette (or aerosol generating system/material) according to claim 5, characterized in that the organic acid is selected from the following pharmaceutically acceptable acids: C2-C7 (preferably C2-C6) alkane or Cycloalkane polycarboxylic acid, C2-C14 (preferably C2-C6) alkane or cycloalkane monocarboxylic acid, benzene compound. The hydrogen on the molecular structure of the ring is replaced by one or more carboxyl groups with carbon atoms of C1-C7 (more preferably C1～C6) straight or branched (preferably straight chain) alkane or cycloalkane group, one or more carboxyl group, one or polyhydroxyl carbon number is C2～C7 (preferably C2～C6) straight or branched chain alkane (Preferably straight chain is dominant) Molecular structure of carboxylic acid, furan compound, pyran compound and pyrone compound substituted with hydrocarbon or cycloalkane group and the highest carbon number of the alkane chain in the molecular structure is not higher than C7 (preferably C6) The hydrogen on the ring is controlled by one or more carboxyl groups with carbon atoms of C1～C7 (more preferably C1～C6) linear or branched (preferably linear predominant) alkane or cycloalkane group, one or more carboxyl group, one or more hydroxyl group The number of carbon atoms is C2～C7 (more preferably C1～C6) linear or branched (preferably straight chain) substituted with alkane or cycloalkane group and the highest carbon number of the alkane chain in the molecular structure is not higher than C7 (preferably C6) Carboxylic acid, ascorbic acid, dehydroascorbic acid, (6-)deoxy-L-ascorbic acid, glucoscorbic acid, erythorbic acid, and other molecular structures in which the highest carbon number of the alkane chain is not higher than C7 (preferably C6, more preferably straight Chain dominant) organic acids, and acid salts or acid salts of the above-mentioned polybasic organic acids. The electronic cigarette (or aerosol generating system/material) according to claim 5, characterized in that the organic acid is selected from the group consisting of cis or transmethyl butenedioic acid, dihydroxy cis or fumaric acid, maleic acid ( Maleic acid), fumaric acid (fumaric acid, fumaric acid, fumaric acid), galactonic acid, glucaric acid, itaconic acid (alkenedioic acid), malic acid, Adiponic acid (muconic acid), oxalic acid, malonic acid, succinic acid (succinic acid), glutaric acid, adipic acid, oxalic acid (pyruvate), oxalic acid (oxaloacetic acid, butanone) Diacid), ketoglutaric acid, hexanodioic acid, diethylmalonic acid, citric acid, tartaric acid, aconitic acid, citramalic acid (2-Hydroxy-2-methylbutanedioic acid), dihydroxytartaric acid, acetic acid, Propionic acid, isopropionic acid, butyric acid, isobutyric acid, n-valeric acid, isovaleric acid, valproic acid, caproic acid, isocaproic acid, n-heptanoic acid, isoheptanoic acid, lactic acid, acrylic acid, crotonic acid, isobutylene Acid, pivalic acid (trimethylacetic acid), 2,2-dimethylolpropionic acid, gluconic acid, D or L-gulonic acid, glycolic acid, D-lactic acid, L-lactic acid, hydroxybutyric acid ( Such as α-, β-, γ-type), hydroxyvaleric acid (such as α-, β-, γ-type), hydroxycaproic acid (such as α-, β-, γ-type), dihydroxyvaleric acid, two Hydroxycaproic acid, trihydroxycaproic acid, caprylic acid, capric acid, lauric acid, palmitic acid, anisic acid (methoxybenzoic acid), phthalic acid, benzethanoic acid, benzoic acid, caffeic acid, o/or p / Or m-methylsalicylic acid, salicylic acid, acetylsalicylic acid, ferulic acid, high oxalic acid (4-Hydroxy-3-methoxybenzeneacetic acid), 4-hydroxyisophthalic acid, phenylpropionic acid, P-hydroxybenzoic acid, isophthalic acid, mandelic acid (mandelic acid), mellitic acid, 4,6-dihydroxy-2-methylbenzoic acid (bryoic acid), phenylacetic acid, protocatechuic acid (3, 4-dihydroxybenzoic acid), cumene acid (insoluble), gallic acid, 2,5-dihydroxybenzoic acid, 2,5-dihydroxyphenylacetic acid, dihydrochalcone, 2-furan acrylic acid, furan carboxylic acid , D-galacturonic acid, glucuronic acid, a-pyrone-5-carboxylic acid, ascorbic acid, dehydroascorbic acid, (6-)deoxy-L-ascorbic acid, glucoscorbic acid, erythorbic acid, angelic acid ( (Z)-2-Methyl-2-butenoic acid), camphor acid (diacid), butylmalonic acid, carboxyglutamic acid (carboxyglutamic acid, polycarboxylic acid), cinnamic acid, coumaric acid (o/or p/or m-hydroxy benzene acrylic acid), coumaric acid (oxyindene carboxylic acid, benzofuran carboxylic acid), monoethyl tartaric acid, glucoheptonic acid, glycolic acid, glycyrrhizic acid, glyoxylic acid hydration Compounds, hydroxyglutamic acid, 1-hydroxy-2-naphthoic acid, 3-hydroxy-2-naphthoic acid, imino disuccinic acid, indole acetic acid, isonicotinic acid, 2-keto-L-gulonic acid, Kojic acid, lactobionic acid, trimethyl acetic acid (trimethyl acetic acid, pivalic acid, glutaric acid, pivalic acid), prebenzoic acid (1-carboxy-4-carboxy-2,5-cyclohexadiene- 1-pyruvate), reducing acid (1,2-dihydroxy-3-ketocyclopentene) , Quinic acid, trans-2-butenoic acid (crotonic acid), sorbic acid, edetic acid, triamine pentaacetic acid, pimelic acid, clavulanic acid, ribonucleotides, deoxynucleotides, inosinic acid, α-Methyl furanosinic acid, adenine nucleotides (adenylic acid, AMP), guanine nucleotides (guanylic acid, GMP), cytosine nucleotides (cytidine acid, CMP), uracil Nucleotides (uridine acid, UMP), thymine nucleotides (thymidylic acid, TMP), hypoxanthine nucleotides (inosinic acid, IMP), xanthine nucleotides, tyrosine, tryptophan Acid, cystine, phosphorylated amino acids (such as phosphotyrosine, phosphoserine and phosphothreonine) and acidic amino acids (such as glutamic acid, aspartic acid), and acid salts or acidic acids of the above-mentioned polybasic organic acids salt; Or the inorganic acid is selected from hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, pyrosulfuric acid, sulfurous acid, metabisulfurous acid, thiosulfuric acid, hydrogen sulfate, dihydrogen phosphate, hydrogen sulfite, benzene sulfonic acid, sulfo water Salicylic acid, and acid salts or acidic salts of the aforementioned polybasic inorganic acids. The electronic cigarette (or aerosol generating system/material) according to claim 5, characterized in that the organic acid is selected from volatile organic acids. The electronic cigarette (or aerosol generating system/material) according to claim 5, wherein the organic acid is selected from malic acid, glycyrrhizic acid, tartaric acid, gluconic acid, oxalic acid, galactaric acid, glucaric acid, Acid, aspartic acid, benzoic acid, ascorbic acid, dehydroascorbic acid, (6-)deoxy-L-ascorbic acid, glucoscorbic acid, erythorbic acid, formic acid, acetic acid, phenylacetic acid, caprylic acid, propionic acid, butyric acid, iso Butyric acid, methylbutyric acid, valeric acid, isovaleric acid, methylvaleric acid, caproic acid, isohexanoic acid. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the composition (I) may contain a small or trace amount of free nicotine, and the amount of free nicotine is less than that of the composition (I) 10% of the total amount of nicotine (free and bound). The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the composition (I) may contain a small or trace amount of free nicotine, and the amount of free nicotine is less than that of the composition (I) 1% of the total amount of nicotine (free and bound). The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the content of nicotine salt in the composition (I) is 0.001%-25% (wt/wt). The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that when the composition (I) is in solution or in a solution state, the pH value is usually 3 to 6.9. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the content of the alkali (more alkaline than the nicotine) in the composition (II) is 0.001%-25 %(Wt/wt). The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the composition (II) has a pH value of 7.2-12 when it is in a solution or in a solution state. The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the pKa value of the alkali is greater than 8.5. The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the pKa value of the alkali is greater than 9. The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the pKa value of the alkali is greater than 9.5. The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the solubility of the alkali in water or ethanol (at a temperature of 25°C) is not less than 10 g/kg. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the base is selected from the group consisting of urea, dianos, tromethamine, ethanolamine, diethylethanolamine, diethanolamine, triethanolamine, diethanolamine Ethanol monoisopropanolamine, dihydroxyethyl tert-butanolamine, ethambutol (ethylenediamine dibutanol), isobutanolamine, dipropanolamine, tripropanolamine, triisopropanolamine, Diisopropanolamine, Dibutanolamine, Tributanolamine, Diisobutanolamine, Triisobutanolamine, Dipentanolamine, Tripentanolamine, Diisoamylamine, Triisoamylamine, Dihexanolamine, trihexanolamine, tromethamine, amino monosaccharide or disaccharide, methyl or ethylated amino monosaccharide or disaccharide, caffeine, pyridoxine/octyl, pyridoxamine, pyridine Doxal, thiamine, amino acid, soluble basic salt of amino acid, soluble saccharin salt, glycyrrhizic acid normal salt and its basic salt or basic salt, dihydrochalcone normal salt and its basic salt or basic Salt, creatine, soluble carbonic acid (normal) salt, basic carbonic acid (normal) salt, bicarbonate, percarbonate, soluble sulfurous acid (normal) salt, thiosulfuric acid (normal) salt, phosphoric acid ( Normal) salt, hydrogen phosphate, pyrophosphate (normal) salt and its basic or alkaline salt, alkali metal or alkaline earth metal soluble basic salt, and mixtures thereof. The electronic cigarette (or aerosol generating system/material) according to claim 22, characterized in that the soluble salt is selected from ammonium salts and salts formed with alkali metal or alkaline earth metal ions. The electronic cigarette (or aerosol generating system/material) according to claim 22, characterized in that the soluble salt is selected from sodium salt, potassium salt, calcium salt, magnesium salt, zinc salt, ammonium salt. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the base is selected from the group consisting of deoxyglucosamine, fucosamine and N-ethyl (or form) acyl-fucosamine), Galactosamine, reduced glucosamine, glucosamine, meglumine, meglumine, neomycamine (or N-form (or acetyl) neomycamine), trehalosamine, N-form (or b) group --L-glucosamine, N-acetyl (or form) acyl-L-glucosamine, streptobiosamine, chitobiose, pyridoxine/octyl, pyridoxamine, pyridoxal, thiamine, Lysine, histidine, arginine, asparagine, glutamic acid, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, serine, threonine , Valine, cysteic acid, N-glycylglycine, ornithine, soluble basic salt of amino acid, soluble saccharin salt, normal salt of glycyrrhizin and its basic or basic salt, two Hydrochalcone normal salt and its basic salt or basic salt, creatine salt, and mixtures thereof; the above-mentioned soluble salt is preferably an ammonium salt and a salt formed with an alkali metal or alkaline earth metal ion. The electronic cigarette (or aerosol-generating system/material) according to claim 1, wherein the aerosol or aerosol-generating agent is selected from the pharmaceutically acceptable boiling point or sublimation point at 1 standard atmospheric pressure below 500°C, but Additives not lower than 50°C. The electronic cigarette (or aerosol-generating system/material) according to claim 1, wherein the aerosol or aerosol-generating agent is selected from pharmaceutically acceptable boiling point or sublimation point lower than 350°C under 1 standard atmospheric pressure, but Additives not lower than 60°C. The electronic cigarette (or aerosol-generating system/material) according to claim 1, wherein the aerosol or aerosol-generating agent is selected from pharmaceutically acceptable boiling point or sublimation point of less than 250°C at 1 standard atmospheric pressure, but Additives not lower than 70°C. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the aerosol or aerosol generating agent is selected from the following pharmaceutically acceptable additives: low boiling point or sublimation point sugar; low boiling point or sublimation point Polyols; low boiling or sublimation point glycols; low boiling or sublimation point monohydric alcohols; low boiling or sublimation point acids; low boiling or sublimation point ethers, aldehydes or ketones; low boiling or sublimation point esters; and mixtures thereof; Low boiling point or sublimation point means that it is lower than 450°C but not lower than 70°C. The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the aerosol or aerosol generating agent is selected from 1,3-dihydroxyacetone, 1,3-dihydroxyacetone dimer, 2 -Deoxy-L-ribose, 2-deoxy-D-ribose 2-Deoxy-D-ribose, arabinose, erythrose, erythrulose, D-xylulose, fructose, ribose, xylose, glucose, sorbose Sugar; glycerol, xylitol, sorbitol, erythritol; propylene glycol, butylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2 -Caprylyl glycol; monohydric alcohols with C2-C14 atoms, menthol, borneol, borneol, isoborneol; lactic acid, benzoic acid, phenylacetic acid, vanillic acid, salicylic acid, aspirin, atoms with C8-C14 The fatty acid; poloxamer, polydi～hexaglycerin, polydi～hexapropylene glycol, polydi～hexaethylene glycol, 1,1-propylene glycol and 1,1-propylene glycol poly(/condensation) ether, 2 ,2-propylene glycol and 2,2-propylene glycol poly(/condensation) ether, 1,1-propylene glycol and 2,2-propylene glycol poly(/condensation) ether, 1,1,1-glycerol Ether formed by poly(/condensation) with 1,1,1-glycerol, ether formed by poly(/condensation) of 1,1-propylene glycol and 1,1,1-glycerol, 2,2-propylene glycol Poly(/condensation) ether and 1,1,1-glycerol poly(/condensation) ether, tetrahydrofuran polyethylene glycol ether (its chemical name: α-[(tetrahydro-2- (Furanayl)methyl]-ω-hydroxy-poly(oxy-1,2-ethylenediyl)), 1,3-dioxane-5-ol, 1,3-dioxolane-4-methanol , 2,2-Dimethyl-1,3-dioxolane-4-methanol; vanillin, ethyl vanillin, camphor; fatty acid esters with glycerol atoms from C1 to C8, triethylene glycol diethyl Acid esters, fatty alcohol esters with C1-C6 lactic acid atoms, C1-C18 fatty acids with C1-C6 fatty acids, diethyl suberate, dimethyl dodecanedioate, Dimethyl tetradecanedioate, C2-C6 fatty alcohol ester with C1-C6 atoms, dodecenyl acetate, benzyl benzoate, phenethyl phenylacetate, ethyl vanillate , Propylene carbonate, 1,3-propanediol monolactate, 1,3-propanediol monoethyl, 1,3-propanediol monopropyl; water; or a mixture thereof. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the aerosol or aerosol generating agent is selected from the group consisting of glycerin, xylitol, sorbitol, erythritol; propylene glycol, butylene glycol , 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol; ethanol, tert-butanol, pentanol, adipic acid; poloxamer 105 or 124, poly di-hexaglycerin, poly di-hexa propylene glycol, poly di-hexa ethylene glycol; glycerol triacetate, glycerol diacetate formate, glycerol dicarboxylate acetate, glycerol diacetate propionate , Glycerol tripropionate, triethylene glycol diacetate, triethyl citrate, diethyl malate, diethyl succinate, propylene carbonate, tetrahydrofuran polyethylene glycol ether (its chemical name is: α-[(Tetrahydro-2-furnatyl)methyl]-ω-hydroxy-poly(oxy-1,2-ethylenediyl)), 1,3-dioxan-5-ol, 1,3 -Dioxolane-4-methanol, 2,2-dimethyl-1,3-dioxolane-4-methanol, 1,3-propanediol monolactate, 1,3-propanediol monoethyl, 1,3-propanediol monopropyl ester; water; or a mixture thereof. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the compositions (I) and (II) are liquid mixtures (at room temperature and 25°C) or solutions. The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the composition (I) and the composition (II) are both liquid and added to the smoking set during use. The electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the composition (I) and the composition (II) are both liquid and have been packaged in the cartridge. The electronic cigarette (or aerosol generating system/material) according to claim 1, wherein the composition (I) and (II) are respectively aerosolized or vaporized or aerosolized by two independent and unconnected atomization subsystems Or aerosolized. An electronic cigarette (energetic, good physical satisfaction, low or no choking sensation, low or no irritation, good throat passage, high bioavailability (bioavailability) of nicotine, and good consumer experience) (Or an aerosol generating system/material) composition, characterized in that the composition includes a pharmaceutically acceptable alkali stronger than nicotine (its pKa value is greater than the pKa value of the nicotine) and pharmaceutically acceptable An acceptable aerosol or aerosol generating agent, the above composition and a composition containing a pharmaceutically acceptable nicotine salt and a pharmaceutically acceptable aerosol or aerosol generating agent are isolated from each other and not blended together, The above two compounds (all after aerosolization or vaporization or aerosolization or aerosolization) are in aerosolized or vaporized or aerosol or aerosol (aerosol) inhalation (in vivo ( Especially in the lungs (in the alveoli)), (in the body of the user (/consumer) (especially in the lungs (in the alveoli)) meet (produce free nicotine)). An electronic cigarette (energetic, good physical satisfaction, low or no choking sensation, low or no irritation, good throat passage, high nicotine bioavailability (bioavailability), good consumer experience) (Or aerosol generating system/material) composition, characterized in that the composition comprises a pharmaceutically acceptable nicotine (nicotine) salt and a pharmaceutically acceptable aerosol or aerosol generating agent, the above composition and containing The composition of a pharmaceutically acceptable base that is stronger than the nicotine (its pKa value is greater than the pKa value of the nicotine) and a pharmaceutically acceptable aerosol or aerosol generating agent are separated from each other and not blended together , The above two compounds (all after aerosolization or vaporization or aerosolization or aerosolization) are in aerosolized state, vaporized state, aerosol state, or aerosol (aerosol) is inhaled (in vivo) (Especially in the lungs (alveoli))), (in the body of the user (/consumer) (especially in the lungs (alveoli)) meet (produce free nicotine)). A device (kits, device, equipment, unit) for aerosolization or vaporization or aerosolization or aerosolization of an electronic cigarette (or aerosol generating system/material) (for use in accordance with claim 1), characterized in that the The device includes two independent and unconnected atomization subsystems (aerosolization or vaporization or aerosolization or aerosolization of the composition (I) and (II) respectively). A device (kits, device, equipment, unit) for aerosolization or vaporization or aerosolization or aerosolization of an electronic cigarette (or aerosol generating system/material) (for use in accordance with claim 1), characterized in that the The device includes two independent and non-communicating atomization subsystems. The atomization subsystems respectively include a liquid storage chamber/or containing cavity (and its constituent parts), an atomization chamber (and its constituent parts), and a mist Or a smoke channel (and its components) or a guide 1 and an atomization component, the liquid storage chamber/or accommodating cavity and the atomization chamber directly communicate or communicate through the guide 2, the fog or smoke channel or One end of the guide member 1 is in communication with the above-mentioned atomization chamber, and the other end is respectively communicated with a suction (nozzle) hole, or the two mist or smoke channels or the other end of the guide member 1 is near a suction (nozzle) hole ("near "The definition of "is that the distance from the suction (nozzle) hole is not less than 70% of the total length of the channel, preferably 90%, more preferably 95%. The best 99%, within the range) is combined with one The suction (nozzle) hole is connected, or the other ends of the above two mist or smoke channels or guides 1 converge at a suction (mouth) hole and communicate with it, and the above two liquid storage chambers/or accommodating chambers are isolated and not connected , The isolation between the above two atomization chambers is not connected, the isolation between the above two mist or smoke channels or the guide 1 is not connected (except for the suction (nozzle) hole or the "near" defined above), and the two guides 2 above Isolation is not connected. The device according to claim 39, wherein said atomization chamber is a hollow continuous cavity. The device according to claim 39, wherein said atomization chamber is a discontinuous cavity. The apparatus according to claim 39, wherein said atomizing chamber is a micropore in a material containing a large number of micropores. The device according to claim 39, wherein the atomization chamber is a non-woven fabric containing a large number of micropores, ceramics, glass, metals, and plastics. The device according to claim 39, wherein said guide member 2 is a material containing fine pores. The device according to claim 39, wherein the guide member 2 is a non-woven fabric, ceramic, glass, metal, or plastic containing microscopic channels. The device according to claim 39, characterized in that said guide member 2 is a hollow introduction tube. The device according to claim 39, characterized in that said atomizing component comprises a heating type or/and a vibration type or/and a compression type atomizing component. The device according to claim 39, characterized in that said atomizing component comprises a resistance heating type or an electromagnetic (oscillation) heating type or/and an ultrasonic vibration type atomizing component. The device according to claim 39, wherein said atomizing component comprises an ultrasonic vibration atomizing component. The device according to claim 39, characterized in that the device further comprises a housing, a power supply assembly, and necessary accessories. The device according to claim 39 or 50, characterized in that the device further comprises a cartridge, a control assembly, and a (pneumatic) switch assembly. The device according to claim 39 or 50, wherein the casing is provided with a cigarette holder and a vent hole, the suction (mouth) hole is located in the cigarette holder, and the vent hole communicates with the air inlet of the atomization chamber, The air outlet of the atomization chamber is in communication with the mist or smoke channel or guide 1. A device (kits, device, equipment, unit) for aerosolization or vaporization or aerosolization or aerosolization of an electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the device comprises A cigarette-shaped cavity housing (4), a power supply (2), a cartridge (3) and a cigarette stick accessory, and the power supply (2) and a pneumatic switch are sequentially arranged in the housing from front to back (7), a high-frequency generator (8), a magnetostrictive vibrator (9) and an electromagnetic induction heater (10) with two chambers (liquid storage chamber/or containment chamber) separated from each other and separated from each other Or a pneumatic switch (7), a power supply (2), a high-frequency generator (8), a magnetostrictive vibrator (9) and two compartments (liquid storage chamber/ Or the electromagnetic induction heater (10) of the cavity), wherein the high-frequency generator (8) is connected to the magnetostrictive vibrator (9), electromagnetic induction heater (10) and pneumatic The switch (7) is connected; The rear end of the shell (4) is connected with the cartridge (3), and two compartments (liquid storage chamber/or containing Cavity) (31); The vapor or smoke channels in the electronic cigarette (the cigarette rod attachment) are spaced apart and not communicated with each other. A device (kits, device, equipment, unit) for aerosolization or vaporization or aerosolization or aerosolization of an electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the device Including an outer casing, a cigarette holder, necessary accessories and an ultrasonic atomization device; the outer casing and the cigarette holder have two isolated and incommunicable mist or smoke channels, one end of which is communicated with the air outlet on the aforementioned cigarette holder, and the other end is connected with the aforementioned ultrasonic The aerosol outlet in the atomization device communicates; the ultrasonic atomization device includes an inner housing (10), a power supply (12), a liquid storage part (liquid storage chamber/or accommodating cavity) (14), and a mesh member (20) ) And a vibration source (30), the housing (10) is formed with a liquid storage portion (liquid storage chamber/or containing cavity) (14), and the liquid storage portion (liquid storage chamber/or containing cavity) (14) ) (Middle) is separated from each other, and the upper end is provided with an openable and closable liquid filling port, and is provided with an aerosol outlet. The aerosol outlet and the mist or smoke channel communicating with it are (middle) isolated from each other In the same way, the mesh member (20) is embedded in the aerosol outlet, the mesh member (20) is a porous mesh structure with a plurality of micropores (21), and the vibration source (30) ) Is connected to the mesh member (20), the vibration source (30) is electrically connected to the power source (12), and the vibration source (30) is energized to generate vibration and drive the mesh member (20) ) Vibrate to vibrate and atomize the liquid near the mesh member (20); the fine hole (21) penetrates the mesh member (20) so that the mist after the liquid atomization can flow out along the fine hole 21, The mesh member (20) is electrically connected with the power source (12), and the mesh member (20) can generate heat after being energized and heat and atomize the liquid near the mesh member (20). A device with an oil cup (kits, device, equipment, unit) for aerosolization or vaporization or aerosolization or aerosolization of an electronic cigarette (or aerosol generating system/material) according to claim 1, It includes a casing (1) and a control component (2), a battery (3) and an atomizer (4) arranged in the casing (1). The control component (2) is connected to the battery (3) and the atomizer respectively. The heating wire (41) of the device (4) is electrically connected, characterized in that: the housing (1) is also provided with an oil cup (liquid storage chamber/or accommodating cavity) (5) for containing smoke liquid, so The atomizer (4) and the oil cup (liquid storage chamber/or accommodating cavity) (5) are arranged adjacently, and the oil cup (5) is provided with an e-liquid outlet (51) at one end of the atomizer (4) , The e-liquid outlet (51) is encapsulated with a material (52) with micropores, and the heating wire (41) of the atomizer (4) is arranged close to the material (52) with micropores , The atomizer (4) and the oil cup (liquid storage chamber/or accommodating cavity) (5) have two chambers (liquid storage chamber/or accommodating chamber) which are separated from each other, and the smoke liquid The outlet (51) and the fog or smoke channel communicating with it are isolated and not communicated with each other. A device (kits, device, equipment, unit) for aerosolization or vaporization or aerosolization or aerosolization of an electronic cigarette (or aerosol generating system/material) according to claim 1, characterized in that the device Including upper and lower shells, power supply components, necessary accessories and 2 independent and unconnected atomization subsystems; the lower shell contains power supply components, atomization subsystems, and two isolated and unconnected mist or smoke channels, One end of the mist or smoke channel communicates with the above atomization subsystem, and the other end communicates with the mist or smoke channel in the upper shell described below; the upper shell is a cigarette holder, and its long side is connected with the lower shell, and the short There are two air outlet holes on the side of the nap, and there are two isolated and incommunicable fog or smoke channels inside, one end of which communicates with the air outlet hole, and the other end communicates with the fog or smoke channel in the lower shell. The device (kits, device, equipment, unit) according to claim 56, wherein the independent atomization subsystem includes a liquid storage chamber/or a containing cavity (and its components), an atomization chamber (and Component), a vapor or smoke channel (and its components) or guide 1 and an atomizing component, the above-mentioned liquid storage chamber/or accommodating cavity and the above-mentioned atomizing chamber directly communicate or communicate through the guide 2, The fog or smoke channel or guide 1 is the fog or smoke channel in the upper and lower shells, the two liquid storage chambers/or the accommodating chambers are isolated and not connected, and the two atomization chambers are isolated and not connected, The two guides 2 are isolated and not connected, and the two fog or smoke channels or the guides 1 are isolated and not connected.

Images